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Nucleoside derived antibiotics to fight microbial drug-resistance: 
New Utilities for an Established Class of Drugs?♯ 
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School of Pharmacy and Pharmaceutical Sciences, Cardiff University, 
Redwood Building, King Edwards VII Avenue, Cardiff, United Kingdom. 
♯This work is dedicated to the memory of Prof. Chris McGuigan, a great colleague 
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Abstract 
Novel antibiotics are urgently needed to combat the rise of infections due to drug-
resistant microorganisms. Numerous natural nucleosides and their synthetically 
modified analogues have been reported to have moderate to good antibiotic activity 
against different bacterial and fungal strains. Nucleoside-based compounds target 
several crucial processes of bacterial and fungal cells such as nucleoside metabolism 
and cell wall, nucleic acid and protein biosynthesis. Nucleoside analogues have also 
been shown to target many other bacterial and fungal cellular processes though these 
are not well characterised and may therefore represent opportunities to discover new 
drugs with unique mechanisms of action. In this perspective we demonstrate that 
nucleoside analogues, cornerstones of anticancer and antiviral treatments, also have 
great potential to be repurposed as antibiotics so that an old drug can learn new tricks. 
Introduction  
 Microbe is an umbrella term describing microscopic living organisms from six major 
groups: bacteria, viruses, fungi, protozoa, algae and archea.1 Some of these microbes 
are essential for the health and survival of humans, animals and plants, whereas others 
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are pathogenic. Since the 19th century, it has been known that microbes can be the 
cause of serious infectious diseases. Antibiotics are routinely used to treat bacterial 
infections, and some of these drugs are also effective against fungi and protozoa. 
However, the efficacy and ease of access of antibiotics has led to the development of 
drug-resistance.2 Bacteria and fungi possess an incredible ability to adapt in response 
to antibiotics, they are able to rapidly evolve mechanisms that interfere with an 
antimicrobial’s mode of action. Acquired antibiotic-resistance can arise by a variety 
of mechanisms, primarily: enzymatic inactivation of the antibiotic, inhibition of its 
cellular uptake or increase of its efflux from the cell, and/or alteration of the target 
site such that the antibiotic cannot recognize it. These adaptations often result from 
the spontaneous mutation of a microbial gene and selection in the presence of the 
antibiotic. Most, but not all, antibiotic resistance genes are encoded by plasmids 
leading to heritable resistance.3,4, 5 Examples of resistant microbial strains can be 
found for every class of antibiotic, regardless of their mechanism of action. 
Antibiotic resistance is a natural phenomenon that has been enhanced by antibiotic 
misuse and by the increasing incidence of immunosuppression, meaning there are 
more individuals who are susceptible to infection. Failure to take antibiotics correctly 
or strictly when necessary has been proven to have drug resistance as consequence. 
Farm animals fed with antibiotics also became reservoirs for antibiotic-resistant 
bacteria that can be easily transmitted to humans. Once resistance has emerged, 
subsequent dissemination of the resistant strain is easy and can be facilitated by 
crowded living conditions and poor hygiene standards.  
The rise of antibiotic resistance and a concurrent reduction of the investment of the 
pharmaceutical companies in the development of new antibiotics, pose a serious 
threat to the entire world population.4 A 2014 Word Health Organization’s report 
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revealed that antimicrobial resistance is spreading across the world and is threatening 
the effective prevention and treatment of common infections caused by bacteria, 
parasites, viruses and fungi.5 It has been estimated that if no concerted effort to 
discover and develop new antibiotics is made by all countries, by 2050 the number of 
deaths per year due to antibiotic-resistant infections will reach 10 million, with an 
associated cost to the global economy of $1 trillion.6  
According to a recent report,4 third-generation cephalosporins, which are the 
treatment of  last resort for gonorrhoea, now appear to be failing, leading to 
untreatable gonococcal infections. Resistance to fluoroquinolones, which are one of 
the most commonly used antibacterial drugs for the oral treatment of Escherichia coli 
infections of the urinary tract, is now widely reported. Common intestinal bacterial 
infections, usually treated with carbapenem antibiotics, are now life-threatening due 
to the resistance developed by these bacteria. Other examples of important drug 
resistant bacteria in humans are methicillin-resistant Staphylococcus aureus (MRSA), 
Clostridium difficile, Salmonella, Chlamydia, and Mycobacterium tuberculosis. 
Drug-resistant fungi also cause both acute and chronic infections associated with high 
morbidity and mortality. Invasive Candida infections are the fourth leading cause of 
hospital-acquired blood infections, and they are associated with a high mortality. 
Besides Candida, antifungal resistance occurs in other fungi such as Aspergillus and 
Cryptococcus neoformans, which are major opportunistic fungal pathogens in 
immunocompromised individuals e.g. HIV-infected patients and those receiving 
immunosuppressive treatment for cancer, organ transplantation, and other serious 
medical conditions. 
A coordinated set of strategies is needed to fight the global threat of antimicrobial 
resistance. Improving infection, prevention and control practice together with the 
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optimization of prescribing practice are critical steps that need to be taken. 
Professional education and training are essential to optimize the consistency in 
prescription. Better access to, and an improved use of surveillance data, could be used 
to drive reductions in antimicrobial prescribing rates and total antibiotic consumption. 
It would certainly be necessary to improve the public engagement and to strengthen 
international collaboration.  Further to these actions, one of the most important 
measures to tackle antibiotic resistance and to prevent its spread worldwide, is 
promotion of research and development of novel antimicrobial agents. Unfortunately, 
only a few classes of antibacterial drugs have been identified in the last 50 years of 
research.7 As such, the identification of new therapeutic targets and the development 
of novel drugs, with the ability to subvert resistance are urgently needed. 
Nucleosides and nucleotides are essential molecules for the life processes of all living 
organisms, including microbes, playing pivotal roles in most fundamental cellular 
metabolic pathways. For this reason, synthetic analogues of nucleosides have been 
extensively investigated as therapeutics and have become mainstays of antiviral and 
anticancer treatment.8 Naturally occurring nucleosides isolated from bacteria and 
fungi are well known for their diverse biological activities.9-16 However, the 
antibacterial and antifungal potential of nucleoside analogues has not been fully 
exploited yet; hence, recognition of these important biological properties could 
therapeutic potential of this class of compounds as antibiotics. 
New antimicrobial drugs, potentially with new mechanisms of action, are needed to 
address the growing problem of resistance. After a brief introduction highlighting the 
structure of bacteria and fungi and their potential therapeutic targets, we will discuss 
the current knowledge of nucleoside and nucleotide analogues possessing 
antimicrobial activity. This perspective will be limited to the potential of this class of 
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compounds for the treatment of bacterial and fungal infections, focusing on the new 
therapeutic utilities for these drugs. An account on the state of the art of anti-
mycobacterial nucleoside and nucleotide analogues for the treatment of tuberculosis 
has been recently published,17 therefore no specific attention will be dedicated to this 
microorganism. This Perspective covers the efforts directed toward the identification 
of natural and modified nucleoside analogues active as antibiotics, up to early 2016. 
This overview is followed by a discussion of the importance of nucleosides as 
antibacterial and antifungal drugs and will, hopefully, provide valuable information to 
aid the development of novel nucleoside analogues against new therapeutic targets.  
Bacteria: Structure and drug targets 
Bacteria are prokaryotic cells that, unlike eukaryotic cells, do not have a well-defined 
nucleus surrounded by a nuclear envelope (Figure 1).  Bacteria are approximately ten 
times smaller than eukaryotic cells, with sizes ranging between 0.2 and 700 µm in 
diameter. They have five key structural components: a nucleoid and plasmids 
containing the genome and any supplementary genetic information; ribosomes which 
are critical for protein synthesis; the cell membrane and cell wall form protective cell 
barriers, with the latter protecting the cells against osmotic stress and physical 
damage,.18 Additional bacterial cell features include the flagella, responsible for 
propulsion/movement, inclusion bodies, responsible for the mineral storage of the 
cell, and pili, which are used for the attachment to the host and for bacterial 
conjugation. (Figure 1). Bacteria are broadly classified into two types: Gram-positive 
and Gram-negative. Gram-positive bacteria have a thick cell wall, which is made up 
of many layers of peptidoglycan. Running perpendicular to the peptidoglycan sheets 
is a group of anionic glycopolymers called teichoic acids. Gram-negative bacteria 
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have comparatively thin cell walls, composed of only a few layers of peptidoglycans 
and surrounded by an outer membrane containing lipopolysaccharides (LPS).18  
 
Figure 1. General structure and inhibition targets of bacteria’s cell. 
Key targets for the treatment of bacterial infections are the various enzymes involved 
in the synthesis of the cell wall, DNA, proteins and phospholipid membrane, along 
with enzymes such as DNA gyrase and RNA polymerase, crucial for bacterial 
replication.19  
The bacterial cell wall is an important antibiotic target. Cell wall peptidoglycan 
consists of parallel strands of a polysaccharide composed of Nacetylglucosamine 
(GlcNAc) and N-acetylmuramic acid (MurNAc) in β-(1,4)-linkage (Figure 2). The 
lactyl side chain of MurNAc continues in a pentapeptide of structure L-Ala-D-Glu-X-
D-Ala-D-Ala, of which X is L-Lys in Gram-positive and meso-diaminopimelic acid 
(DAP) in Gram-negative bacteria.20 The cross-linked structure of peptidoglycan 
confers mechanical strength and shape to the cell and provides a barrier to withstand 
internal osmotic pressure. Nevertheless, it has sufficient plasticity to allow cell growth 
and division. Its fast turnover makes peptidoglycan an attractive target for 
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antibiotics.21 Synthesis of peptidoglycan is a three-stage process that occurs in the 
cytoplasm, as well as in the inner and outer part of the plasma membrane. 
Peptidoglycan synthesis involves several different enzymes, most of which represent 
attractive targets for development of antibacterial therapeutics (Figure 2).22  
 
Figure 2. Peptidoglycan structure and biosynthesis. 
Fungi: Structure and drug targets 
Fungi are eukaryotic unicellular or multicellular microorganisms. Therefore they have 
a well-defined nucleus as well as membrane-bound organelles.23, 24 The biggest 
difference between fungal and mammalian cells is the presence, in fungi, of an outer 
cell wall. The fungal cell wall is dynamic system that provides the cell with 
mechanical strength and protection (Figure 3).24 Other significant differences can be 
found in the membrane portion, which in fungi contains ergosterol and in mammals 
contains cholesterol.24 The biosynthetic pathway for ergosterol is a specific branch of 
the mevalonate pathway which, being fungi-specific, represents an attractive target 
for antifungal therapy.23 Additional therapeutic targets could include regulators of 
fungal DNA biosynthesis or cell division e.g. mitotic spindles. 
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Figure 3. General structure and inhibition targets of the fungal cell. 
 
The fungal cell wall is comprised of three main building blocks: chitin (a polymer of 
N-acetylglucosamine); glucans, (glucose polymers that serve as cross-link between 
chitin polymers and give rigidity to the cell wall) and glycoproteins.25 The formation 
and remodelling of the fungi cell wall involves numerous biosynthetic pathways and 
the concerted actions of hundreds of fungal proteins.  
The chitin and glucan components are synthesized on the plasma membrane and are 
extruded into the cell wall space during their synthesis ( Figure 4). The synthesis of 
chitin is mediated by chitin synthase, an integral membrane enzyme that catalyses 
transfer of N-acetylglucosamine from uridine diphosphate (UDP)-N-
acetylglucosamine to a growing chitin chain.  
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Polymers of glucan are generated by the plasma-membrane associated glucan 
synthases. Within each glucan chain (approximately 1500 glucose units) some of the 
glucose residues become sites at which additional glucans are attached to generate 
branched chains that are in turn cross-linked together and to the chitin. 
Glycoprotein synthesis begins in the endoplasmic reticulum with co-translational 
addition of N-linked oligosaccharides. In the Golgi apparatus, the glycosyltransferase 
further modifies proteins by addition of sugars to generate O-linked and N-linked 
oligosaccharides. In addition, some glycoproteins are further functionalized with a 
glycophosphadityl inositol (GPI) anchor. These glycoproteins are then secreted into 
the cell wall space where they are covalently combined with sugars units of chitin or 
glucans, via their N-, O-, and GPI sugar units. Enzymes such as glycosyl hydrolases 
and glycosyl transferases assist this process.  
 
  
 Figure 4. Chitin structure and biosynthesis. 
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Chitin synthesis is the target of a range of antifungal agents, including nucleosides.26 
The inhibition of glucan synthesis has also been extensively pursued as a means of 
disrupting wall formation and preventing fungal growth.27  
Both glycosylation and GPI anchor addition have also been shown to be very 
important processes in the cell wall biosynthesis. As such, disruption of these 
pathways is predicted to have significant effects on the structure and function of the 
fungal cell wall. 
Nucleoside analogues as cell wall inhibitors 
Since they are not present in mammal cells, the cell wall of bacteria and fungi 
represents an important target for different classes of antibiotics and this target still 
possess a great potential for the development of selective therapeutics.  
Numerous natural products with nucleosidic structures have been isolated and found 
to be inhibitors of the cell wall biosynthesis.12, 14 Synthetic analogues have been 
further produced in order to expand the bacterial and fungal spectrum of activity and 
to improve bioavailability. The following sections provide an overview of several 
classes of nucleoside analogues whose antibacterial activity was found to depend on 
the inhibition of cell wall biosynthesis.  
Nucleoside analogues as inhibitors of peptidoglycan biosynthesis  
Important classes of antibacterial nucleoside analogues have been harvested from 
natural sources and found to inhibit peptidoglycan synthesis, by targeting the MraY 
enzyme. Among them, the tunicamycins 1a-l, originally isolated from S. 
lysosuperficus and S. chartreusis in 1971, mimic the bis-substrate intermediate of N-
acetyl-D-hexosamine-1-phosphate translocase or MraY.28 This class of antibiotics 
consists of five structural units: uracil (A), ribose (B), galactosamine (C), N-
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acetylglucosamine (D), and a fatty acid (R) (Figure 5).29 The B and C portions of 
tunicamycin structure constitute an undecose moiety named tunicamine.30 Because of 
their structure, these nucleoside antibiotics target both the bacterial MraY and the 
eukaryotic GlcNAc-1-P transferase. Targeting MraY inhibits synthesis of precursors 
for components of bacterial cell wall and inhibiting GlcNAc-1-P transferase prevents 
N-glycosylation of eukaryotic proteins.29, 31, 32 The antibacterial effect of tunicamycins 
is directed primarily against Gram-positive bacteria, especially those of the Bacillus 
genus (MICs = 0.1–20 μg mL-1).33 
 
Figure 5. Structures of tunicamycins 1a-l.  
 
Several years after the discovery of tunicamycin, another class of natural antibiotics 
named Streptovirudins 2a-j were isolated as a complex mixture consisting of ten 
closely related components, from fermentation of Streptomyces sp. These compounds 
were found to be structurally similar to tunicamycins and in fact, streptovirudins 2i 
and 2j were later identified as tunicamycins 1a and 1b (Figure 6). The main 
difference between these two classes of natural products lies in the nucleobase (X): 
uracil in tunicamycins and mainly dihydrouracil in streptovirudins (Figure 6). 
The streptovirudin complex, which is inactive against Gram-negative bacteria, does 
exhibit antibiotic activity against Gram-positive bacteria, with MIC values between 
0.31 and 10 g/mL against different strains of Bacilli.  Moderate activity was also 
observed against Mycobacteria sp., with the activity of streptovirudin 2d as low as 
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MIC = 3.1 g/mL against M. smegmatis.34   In acute toxicity studies in mice, the 
streptovirudin complex was moderately tolerated if administered orally, but more 
toxic when administered subcutaneously, intravenously or intraperitoneally.  
 
 
Figure 6. Structures of streptovirudins 2a-j. 
 
Another series of natural nucleoside analogues, structurally related to tunicamycin 
and streptovirudins, are corynetoxins 3a-n, isolated from Corynebacterium sp.35 The 
corynetoxins differ from tunicamycins and streptovirudins because they contain 
longer fatty-acid residues (R), -hydroxy alkyl chains in addition to the common -
unsaturated and saturated series (Figure 7). The antibacterial activity of these 
analogues was found to be similar to tunicamycins, with MIC values ranging between 
0.1 and 0.8 g/mL against different Bacillus strains.38 Similarly to tunicamycins, 
evidence of toxicity was found for this class of compounds, with LD50 values of 137 
g/kg on nursling rats (the LD50 of tunicamycin is 132 g/kg in the same assay).35 
The toxicity derives from the inhibition of the mammals protein glycosylation enzyme 
GlcNAc-1-P transferase. 
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Figure 7. Structures of corynetoxins 3a-n. 
The off-target inhibition of mammalian glycoprotein biosynthesis, precluded the use 
of translocase I (MraY), tunicamycin, streptovirudins and corynetoxins as therapeutic 
antibiotics, thus stimulating the search for more selective agents. Subsequent research 
led to the discovery of two new classes of antibiotics named liposidomycins and 
mureidomycins, which are able to inhibit the bacterial translocase I without being 
toxic in mice. 
Liposidomycins are characterised by a complex structure containing 5'-substituted 
uridine (A), 5-amino-5-deoxyribose-2-sulfate (B), perhydro-1,4-diazepine (C), and 
fatty acyl moieties (R1) (Figure 8).36, 37 Despite the structural similarities to 
tunicamycins, liposidomycins are specific MraY inhibitors, and show no in vivo 
toxicity up to a concentration of 500 mg/kg.38 Although liposidomycins have potent 
MraY inhibitory activity in vitro (IC50 = 0.03 g/ml), their antimicrobial activity in 
whole cell assay was lower than expected, potentially due to poor permeability 
through the bacterial cell membrane.39 Figure 8 shows the structures of the natural 
liposidomycin 4a-j containing the sulfate and 3-methylglutaric acid moieties, which 
were the first to be isolated from the culture broth of S. griseosporeus.39 More 
hydrophobic analogues, lacking either the sulfate group 5a,c, the methylglutaryl 
moiety 6a-j or both the two groups 7a,c were isolated later in the fermentation broth 
of the same microorganism by the change of medium components (Figure 8).40-42 The 
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order of peptidoglycan inhibition was found to be 4a-j > 5a,c > 7a,c > 6a-j, 
suggesting that the 3-methyl-glutaryl moiety plays a critical part in the MraY 
inhibition. Compounds 6a-j and 7a,c had similar in vitro activity compared to 4a-j 
and 5a,c but better in vivo properties, due to their higher lipophilicity and consequent 
improved membrane permeability.43 Among all the analogues, liposidomycin 6c was 
one of the most active against M. avium complex  (MIC = 1.2-12.5 g/ml).  
  
 
Figure 8. Structures of natural 4a-j and synthetically modified liposidomycins 5a,c, 6a-j; 7a, c. 
 
In order to elucidate the pharmacophore of this family of antibiotics, less complex 
liposidomycins analogues were synthesised and tested as MraY inhibitors (Figure 
9).44, 45 In this study it was demonstrated the lipophilic fatty acid chain (R1) was 
essential for activity as its removal generated a 200-fold less active analogue 8 
(Figure 9). Both the 5’’-amino group and the uracil moiety were found critical for the 
inhibition of the bacterial translocase. Modification of the uracil nucleobase via 
reduction of its double bond and methylation of the imide group led to compounds 
lacking of any inhibitory activity in translocase assay. Compound 9a, a simplified 
molecule based only on the liposidomycin core structure, was found to be a moderate 
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MraY inhibitor (IC50 = 50 μM), while compounds 9b and 9c, higher homologues of 
9a containing an additional stereocentre at the 5’ position, showed different MraY 
inhibitory activities. In particular, only the (S)-isomer 9c showed significant activity 
against MraY with an IC50 value of 5 μM (Figure 9).44, 45  
A compound with a hydroxyl group at the 5” position was found totally inactive in 
translocase inhibitory assay. Among a series of compounds with different amines at 
5” position, compounds 10a-d (Figure 9) were endowed with MraY inhibitory 
activity, proving that the primary amine can by replaced by isosters (i.e., secondary 
amines, amidine or guanidine). The activities were nevertheless low, with IC50 
ranging from 25 to 50 μM against MraY.44 
In order to further define the active pharmacophore, additional analogues were 
synthesised by modification of the hydroxyl group patterns 11a-d (Figure 9).46 
According to these investigations, only the 3’’-hydroxyl group (R3) was found to be 
crucial for the inhibition of MraY. Instead, the absence of the 2’’-hydroxyl (R2) or 
both the 2’- and 3’-hydroxyls (R and R1) resulted in a decrease in activity. The 
exclusive removal of the 2’-hydroxyl group (R) had little impact on the activity while 
the absence of the 3’- hydroxyl (R1) gave rise to an inhibitor, which was five times 
more potent than the parent compound 10a. In particular, compounds 11a-c had anti-
MraY activities with IC50 ranging from 10 to 80 μM, while compound 11d was 
completely inactive.46 From these investigations it was clear that the structural 
features that appear to be important for high inhibitory activity against MraY include 
the absence of hydroxyl at the 3’-position, a 5’S chiral center, a primary amine group 
at the 5’’-position, and an unmodified uracil moiety. Replacement of the complex 
diazepanone ring with simple lipophilic substituents was also shown to improve 
activity 12a-e (Figure 9).47 The longer the chains the more powerful the compounds 
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were found to be in whole cell assays. In fact, antibacterial activity was detected only 
for compounds with alkyl chain with n = 9 to 13 methylene units, reaching MIC
 
values against S. aureus as low as 2.5 μg/mL.43 On the other hand, the in vitro 
inhibitory activity against MraY was very similar for all compounds with different 
alkyl chain lengths, with IC50 values ranged between 0.33 and 0.90 μM.47 This may 
suggest that length and lipophilicity of the hydrocarbon chain are key features 
necessary for the activity in whole cell assay. 
Simplified gem-difluorinated liposidomycin analogues were also evaluated as MraY 
inhibitors. However, only compound 13 showed moderate activity, with 29 % 
inhibition of MraY at a concentration of 11.4 mM (Figure 9).48 
  
Figure 9. Structure of simplified liposidomycin analogues 8; 9a-c; 10a-d; 11a-d; 12a-e. 
 
Mureydomycins 14a-d, as liposidomycins, belong to the class of uridyl-peptide 
antibiotics. These compounds have a uridyl moiety (A) linked to a peptide chain (C) 
via an enamidic bond (B) (Figure 10).49 Isolated from S. flavidoviridens in 1989, these 
NH
O
ON
O
OH
O
OH
R O
OHOH
10a R = -NH2
10b R = NH
NH
NH
NH
H2N
10d R = NH
10c R =
NH
O
ON
O
R
O
R2
H2N O
R1R3
11a R = R1 = R2 = R3 = OH
11b R = H; R1 = R2 = R3 = OH
11c R1 = H; R = R2= R3 = OH
11d R = R1 = R2= OH;  R3= H
NH
O
ON
O
OH
O
OH
H2N O
OH
12a n = 4
12b n = 7
12c n = 9
12d n = 11
12e n = 13
NHn
NH
O
ON
O
OSO3H
O
OH
H2N O
F
OH
F
13
2'3'' 3'2''
5''
NH
O
ON
O
OHO
OH
H2N O
N
N
O
HOOC
OH
OH 8
NH
O
ON
O
OHO
OH
H2N *O
R
OH
OH
9a R = H
9b R = CH2OH, * = R
9c R = CH2OH, * = S
5'5''
  17 
analogues were found to be potent in vitro especially against Pseudomonas 
aeruginosa (MICs = 1.5-12.5 μg/mL). When evaluated in an infected mice model, 
they also showed ED50 doses ranging between 50 and > 100 mg/kg).50 Analogue 14c 
(Mureidomycin A) showed generally the most potent antibacterial activity against β-
lactam-resistant strains of P. aeruginosa (MICs = 0.1-1.56 g/mL) together with 
remarkable in vivo activity against P. aeruginosa infected mice.51 Compound 14c was 
also found to inhibit selective bacterial translocase MraY without any significant 
effect on the mammalian glycotransferases.52, 53  
Mureydomycins 14e and 14f (Figure 10) were only later identified and showed lower 
anti-pseudomonas activity when compared to 14a.54 
 
Figure 10. Structures of mureidomycins 14a-f. 
 
A structure-function study on mureidomycins55 aimed to examine the role of the 
enamide linkage in the MraY binging and revealed that the peculiar 4’,5’-enamidic 
bond (B; highlighted in the blue square; Figure 10), is not the only key structural 
feature responsible for the MraY enzyme binding. In support of this, compound 15 
(Figure 11), synthesised as a simplified mureydomycin analogue, indeed showed lack 
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of enzyme inhibition.55 Different studies showed the greater importance of the N-
terminal in the peptide chain for MraY inhibition, due most probably to its crucial 
interaction with several of the enzyme’s residues.56 To confirm this, a series of 5’-
uridinyl dipeptide analogues of mureidomycin A in which the diaminobutyric acid 
unit is replaced with a -alanine or N–methyl--alanine were prepared and evaluated 
for their MraY inhibition and antibacterial activity.  The simplified analogue 5’-O-(L-
ala-N-methyl--alanyl)uridine (16, Figure 11), was found to be an inhibitor of MraY 
(97 % inhibition at 2.3 mM), and also active against P. putida at 100 g/mL 
concentration. The activity of such compound was found to be competitive with Mg2+ 
ions suggesting that the primary amino terminus may be able to bind the enzyme in 
place of the Mg2+ cofactor.57 Analogues without either enamide, or diaminobutyric 
acid or N-methyl functionalities were found to be inactive.58 Compounds bearing a 
reduced enamidic portion and different combinations of amino acids in the peptidic 
region were found to inhibit M. tuberculosis growth. The most active compounds 
17a-d (MIC90 = 12.5 g/mL) are reported in Figure 11.59 
 
Figure 11. Structures of simplified mureidomycin analogues 15; 16; 17a-d. 
 
Recently, N-acetylated mureidomycin analogues 18a-h, were identified60 and were 
revealed to be potent growth inhibitors of P. aeruginosa (Figure 12). 
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Figure 12. Structures of N-acetyl mureidomycin analogues 18a-h. 
 
One additional series of uridyl-peptide antibiotics is represented by pacidamycins 
19a-g, which were originally isolated from S. coeruleorubidus.61-63 Their common 
scaffold contains a central N-β-methyl-2S,3S-diaminoburytic acid (A) moiety, which 
is α-amino-capped by a ureido dipeptide (B), β-amino-capped by a single amino acid 
or a dipeptide (C), and carboxy-linked to a 3′-deoxy-4′,5′- enaminouridine (D). 
These compounds showed no activity against Gram-positive bacteria but were found 
to have potent in vitro efficacy against P. aeruginosa (MICs = 4-16 g/mL).63 
Unfortunately, these analogues did not show in vivo activity in mice. Three additional 
analogues 19h-j were later on isolated and had similar in vitro activity to the previous 
analogues against P. aeruginosa (for 19h MIC = 32 g/mL).64-66  
The enamide group of pacidamycins can be hydrogenated, with the retention of 
antibiotic activity, such as in the case of dihydropacidamycin D (20a) (Figure 13) 
with only a minor decrease in the activity (MIC = 64 g/mL) against P. aeruginosa.67 
However, hydrogenation of both the enamidic bond and the nucleobase generated the 
totally inactive tetrahydropacidamycin D (20b) (Figure 13).67 
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Figure 13. Structures of pacidamycins 19a-j, dihydropacidamycin D (20a) and tetrahydropacidamycin 
D (20b). 
Modifications in the peptidic portion of 20a were introduced. The resulting analogues 
showed either retention (MIC = 16 g/mL for 21a-d) or improvement of the 
antibacterial activity (MIC = 4 and 8 g/mL respectively for 21e and 21f) against P. 
aeruginosa (Figure 14). 
Introduction of different nucleobases in the scaffold of pacidamycin caused a drop in 
activity, confirming the requirement for an uracil base for antibacterial activity of this 
class of analogues.68 In a later study, the culture broth of S. coeruleorubidus was fed 
with halogenated phenylalanine analogues, leading to the biosynthesis of differently 
halogenated pacidamycin analogues 22a and 22b.66 These compounds were bio-
assayed against P. aeruginosa and E. coli and the activity was compared to the closest 
structural analogue pacidamycin 19h. The chlorinated analogue 22a exhibited a two-
fold decrease in activity (MIC = 64 g/mL) whilst the fluorinated derivative 22b was 
totally inactive (Figure 14). Both compounds were inactive against E. coli.66 
In 2013 Okamoto et al. carried out the total synthesis of 19i (Figure 13) and tested it 
along with the 3’-hydroxy analogue 23 (Figure 14) in a whole cell assay against P. 
aeruginosa and in an enzymatic assay as MraY inhibitor.69 Compound 23 was found 
slightly less active against MraY (IC50 = 42 nM) than the natural analogue 19i (IC50 
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=22 nM). However, the activity in whole cell assays on different strains of P. 
aeruginosa was improved (MIC = 8-32 µg/mL compared to MIC = 16-64 µg/mL for 
19i).69  
 
Figure 14. Structures of pacidamycin analogues 22a-f; 23a-b; 24. 
 
In 1994 during the course of a screening program for antibiotics with specific activity 
against Pseudomonas sp. another series of uridyl-peptide antibiotics named 
napsamycins 24a-d were isolated from different strains of Streptomyces (Figure 15).70 
The general structure of these compounds contains a N-methyl diaminobutyric acid 
(A), a methionine (B) an ureido group (C), and two non-proteinogenic aromatic 
amino acid residues (D) in a peptide backbone that is linked to a 5'-amino-3'-
deoxyuridine or 5'-amino-3'-deoxydihydrouridine by an enamide bond (E). This class 
of antibiotic showed anti-pseudomonas activity similar to mureidomycins and 
pacidamycins (MIC = 6.25-50 g/ml).70 
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Figure 15. Structures of Napsamycins 24a-d. 
 
Within the series of uridyl-peptide compounds sansanmycins 25a-n, are the most 
recently discovered sansamycin antibiotics (Figure 16). Structurally very similar to 
mureidomycin, pacidamycin and napsamycin, sansamycin antibiotics consist of a 3’-
deoxy uridyl moiety (A) linked to a peptide chain (C) via an enamidic bond (B). The 
difference from the other uridyl-peptide compounds lies in the nature of the amino 
acids of the peptidic chain. Compound 25a, first isolated from Streptomyces sp. in 
2007, showed inhibitory activity against M. tuberculosis and P. aeruginosa with MIC 
values respectively of 10 and 12.5 g/mL.71 Other analogues bearing diverse amino 
acids in the peptidic region were later reported 25b-f.72, 73 Although, these new 
compounds were less active than 25a, compounds 25b and 25c showed similar 
activity against P. aeruginosa and M. tuberculosis (MICs ranging from 8 to 20 
g/mL). 
In 2011, novel synthetic sansamycin derivatives 25o,p were prepared from 25a by N-
alkylation of the primary amino group and the O-alkylation of the tyrosine residue.74 
When evaluated as anti-tuberculosis agents (Figure 16), derivatives 25o and 25p 
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retained activity with MIC values of 16 and 8 g/mL respectively when compared to 
the parent compound 25a (MIC value of 16 g/mL). Compound 25p retained its 
activity (MIC value of 8 g/mL) when tested against M. tuberculosis strains resistant 
to rifampicin and isoniazide.  In the same test, 25a had antibacterial activities with 
MIC values of 16 and 32 g/mL against rifampicin and isoniazide-resistant strains 
respectively.  
In 2014, novel natural sansanmycin analogues were identified 25g-n (Figure 16).75 
Compound 25j was the most potent analogue, with eight-fold improved anti-
tuberculosis activity compared to the parent 25a (MIC = 2 g/mL) and potent anti-
pseudomonas activity (MIC = 8 g/mL). 
  
Figure 16. Structures of natural 25a-n and N-alkylated synthetic sansanmycin analogues 25o,p. 
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Caprazamycins 26a-g, specific inhibitors of MraY, are another series of compounds 
belonging to the family of lipouridyl antibiotics (Figure 17). First reported in 2003 
following isolation from culture broth of Streptomyces sp. MK730-62F, these 
compounds have similar structures to lipidomycins, from which they differ just for the 
lack of the 2’’-sulfate group of the aminoribose (B), and for the presence of a seven 
member diazepanone skeleton (C) together with a permethylated L-rhamnose (E) β-
glycosidically linked to a 3-methylglutaryl moiety (D) (Figure 17).76-78 
These analogues are mainly active against acid-fast bacteria, showing excellent in 
vitro anti-mycobacterial activity against drug-susceptible and multidrug resistant M. 
tuberculosis strains (MIC = 3.13 μg/mL) without significant toxicity in mice.79 
 
Figure 17. Structures of natural caprazamycins analogues 26a-g. 
Caprazol (27a), the common structural motif present in all caprazamycins (Figure 18), 
has been isolated as minor component in the same fermentation culture of 
caprazamycins 26a-g. It can be also prepared synthetically allowing access to several 
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analogues. 80, 81 Hirano et al. tested 27a along with compounds 27b and 27c, in which 
the OH at the 3’’’ position is linked to a palmitoyl chain (Figure 18). 79 The caprazol 
analogue 27a showed no activity against either M. tuberculosis or S. aureus. On the 
other hand, the N-methylated 27b and the N-demethylated 27c palmitoyl derivatives 
showed good activity against S. aureus (MIC = 1.56-6.25 g/mL) and moderate 
activity against Enterococcus faecalis (MIC = 12.5 g/mL). The methyl group was 
found to be important for the activity against M. tuberculosis. Compound 27b was 4-
fold more active than 27c (MICs 6.25 g/mL and 25 g/mL respectively). The same 
research team prepared different caprazamycin analogues lacking either the uridine 
moiety (A), or the aminoribose (B). 79 A third compound 28 bearing an acyclic 
caprazole group was also synthesised (Figure 18).82 These analogues were tested as 
anti-mycobacterial agents, and only the acyclic compound 28 retained antibacterial 
activity against M. tuberculosis (MIC = 6.25 g/mL). 
 
 
Figure 18. Structures of synthetic caprazamycins analogues 27a-c; 28. 
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Other caprazamycin analogues 29a-f were synthesised in 2010 by Ii et al.83 In these 
novel molecules the diazepanone ring was removed and lipophilic chains with amide 
or urea linkages were attached to either the C-7’ or N-6 atom. The acyclic analogues 
29a-f exhibited relatively moderate MraY inhibitory effects: compounds 29a,b (IC50 
=18 and 46 M) were generally more active than 29c-f (IC50 =36- 256 M). 
However, when 29a-f were evaluated against a range of bacterial strains including S. 
aureus, E. faecalis and E. facium their antibacterial activities were largely reduced 
compared to the parent natural products, indicating that the diazepanone moiety was 
not essential for, but contributory to antibacterial activity. In particular, the C-amide 
derivatives 29a,b exhibited weak antibacterial activity against drug-susceptible and 
drug-resistant strains of S. aureus (IC50 = 64 M) and Enterococci sp. (IC50 = 16-64 
M). On the other hand, analogues 29c-f, demonstrated total loss of antibacterial 
activity. The reduced biological activity observed with compounds 29a-f was 
attributed to their excessive flexibility when compared to the natural caprazamycin. 
Therefore, the same authors decided to restrict the conformation of the acyclic 
analogues by linking the nitrogen atom at the 6’-position and the oxygen atom at the 
5’-position of either 29a or 29c (Figure 19).83 As a result oxazolidone-containing 
compounds, lacking the aminoribose and the diazepanone ring were generated. 
Among these compounds, 30a-m showed antibacterial activity with MIC values 
ranging from 8 to 32 g/mL against the bacterial resistant strains S. aureus, E. 
faecalis and E. faecium (Figure 19). Surprisingly, these analogues were only weak 
MraY inhibitors with IC50 of 920-1200 μM, suggesting a different mechanism of 
action. 
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Figure 19. Structures of synthetic caprazamycin analogues 29a,b; 30a-i; 31a,b; 32a,b. 
 
Acidic treatment of a mixture of natural caprazamycins 26a-g afforded another 
simplified caprazamycin analogue 31a lacking of the permethylated (L)-rhamnose (E) 
β-glycosidically linked to a 3-methylglutaryl moiety (D). This analogue was named 
caprazene and represents the core structure of caprazamycins (Figure 20).77 Although 
31a was found to be devoid of any antibacterial activity, its chemically modified 
structures were potent anti-mycobacterial agents (Figure 20).84 Most of these 
analogues have low MIC values down to 0.05 g/mL.84 One of the most active 
derivatives was 31b (CPZEN-45, Figure 20), which surprisingly showed an 
antibacterial spectrum different from that of the natural caprazamycin. In particular, 
the spectrum of 31b was found to be narrower and it was especially effective against 
slowly growing mycobacteria, implying that 31b has a different mode of action from 
caprazamycins. In further study, decaprenyl-phosphate–GlcNAc-1-phosphate 
transferase (TagO), an enzyme involved in the biosynthesis of teichoic acid, was 
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identified as the primary target of 31b in B. subtilis.85The same molecule targets the 
WecA (the orthologue of TagO) in M. tuberculosis. 
32a (A-90289 A) and 32b (A-90289 B) (Figure 20) are nucleoside analogues closely 
related to caprazamycin, which were recently isolated from the culture broth of 
Streptomyces sp. SANK 60405.86-88 These compounds are characterised by the 
presence of a sulfate group on 2’-position of the uridine moiety, and were reported to 
inhibit MraY enzyme at concentrations around 30 ng/mL. In whole cell assay MIC 
values of 32a against different strains of Streptococcus, Enterococcus and 
Staphylococcus ranged between 4 and 16 g/mL.86 
 
Figure 20. Structures of semi-synthetic 31a,b and natural caprazamycin analogues 32a,b. 
 
The search for translocase I inhibitors, led to the discovery of another novel 
nucleoside antibiotic 33 (A-94964) isolated from the culture broth of the strain 
Streptomyces sp. SANK 60404 (Figure 21).89, 90 This compound has a unique 
structure with an extended uronic acid (A) with eight-carbon unit. The oxygen atoms 
at 6’ and 7’ position of this acid, are connected to a pendant ribose unit (B) and to a 
phosphate bridge (C) respectively. The other arm of the phosphate group is then 
connected to a N-acyl glucosamine moieties (D). Despite the substantial structural 
changes, 33 was found to inhibit bacterial MraY with an IC50 value of 1.1 g/m. It 
  29 
showed antimicrobial activities against S. aureus and E. faecalis with MIC values of 
100 and 50 g/mL respectively, without any cytotoxicity against mammalian cell 
lines.89 
More recently, during an active discovery program focused on inhibitors of bacterial 
translocase, researchers at Daiichi-Sankyo Co. Ltd in Tokyo reported additional 
liposidomycin and caprazamycin analogues 34a (A-97065) and 34b (A-
97065OPO3H) and muraminocin 35, which were isolated from culture broths of 
Streptomyces sp. SANK60704 and Streptospotangium sp. SANK60501 respectively 
(Figure 21).91, 92  These antibiotics, which differ only at the acyl group (E), showed 
similar antibacterial activity to liposidomycin and caprazamycins suggesting that 
there is no characteristic structure–activity relationship in the fatty acid side chain. 
Compound 34b with a phosphate group was found 40-times less potent than the 
dephosphorylated analogue 34a.  
In 2015, using a gene-targeting approach, Van Lanen and co-workers discovered 
novel nucleoside-derived antibiotics. In particular, the authors were able to isolate and 
characterize only one of the species detected in actinomycete (Sphaerisporangium sp. 
SANK 60911) culture broth. This new compound, named Sphaerimycin A, has a 
structure (determined by mass spectrometry and NMR) closely related to those of 
muraymycin with which it shares the uridine moiety. Sphaerimycin A is capable to 
potently inhibit translocase I (IC50 between 12 and 65 ng/mL), displaying also 
promising antibacterial activity against different strands of Gram-positive bacteria. 
On the contrary it was found totally inactive against Gram-negative bacteria probably 
as a results of a pronounced efflux.93 (Figure 21)  
  30 
 
Figure 21. Structures of analogues 33, 34a-b and muraminocin 35. 
 
Another important class of natural nucleoside analogues are capuramycins, which 
present in their structures a uridine-5’-carboxamide (A), an unsaturated -D-
mannopyranuronate (B) and a L--amino--caprolactam moiety (C) (Figure 22). The 
first member of this class is the uracil nucleoside analogue 36a, isolated in 1986 from 
the culture filtrate of S. griseus (Figure 22).94-97 Compound 36a proved to have 
selective anti-mycobacterial activities with MIC values of 3 and 12.5 g/mL against 
M. smegmatis and S. pneumoniae respectively. The antibacterial activity was linked to 
the inhibitory activity of MraY (KI = 10 ng/mL).  
In 2003 two capuramycin derivatives, 36b (A-500359A), the methylated version of 
36a, and 36c (A-500359E), lacking instead of the caprolactam moiety, were isolated 
from S. griseus culture (Figure 22).98, 99 Compound 36b was found to have MraY 
inhibitory (IC50 = 0.017 M) and antibacterial activity against M. smegmatis (MIC = 
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6.25 g/mL) similar to capuramycins 36a. On the contrary, although derivative 36c 
was still inhibiting MraY (IC50=0.027μM), it was devoid of any antibacterial activity. 
This result was attributed the hydrophilic nature of this compound, which could 
potentially prevent it from crossing the cell wall and reaching the target enzyme, 
translocase I. Therefore, a number of synthetic derivatives with a variety of 
substituents in place of the diazepan-2-one moiety, were prepared.100 The discrepancy 
in activities of these analogues seemed to be linked to the difference in cell 
permeability. These new capuramycin analogues 36d-g were synthesized from A-
500359E replacing the methyl ester with a variety of amides (Figure 22). When tested 
in whole cell assay the most potent compound was the phenyl amide 36h (MIC = 6.25 
g/mL). The other analogues 36d-g had activities with MIC values ranging between 
12.5 and 50 g/mL. 
Compounds 37a-g were also prepared by acylation of the 2’-hydroxyl of the uridine 
unit together with the acylation of one or both the two hydroxyl groups on the a-D-
mannopyranuronate.101 These modifications caused an increase in cell permeability 
and also of the antibacterial activity. Many analogues were very potent against 
different Mycobacteria strains. The most active analogues were compounds 37a-d, 
with MIC values lower than 0.063 g/mL against M. avium, M. intracellulare and M. 
kansasii. This impressive activity was suggested to be dependent on the excellent 
lipophilicity of these compounds, which enabled them to penetrate the cell membrane 
of Mycobacteria more effectively. It has also been suggested that these compounds 
may work as prodrugs, being converted into the parent compound 36b, within the 
bacterial cell.  
The same research group modified the scaffold of 36b by replacing the diazepam-2-
one moiety with diverse aryl groups.100 Among several aryl derivatives, compound 38 
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(Figure 22) showed MICs between 0.5 and 2 g/mL against different mycobacterial 
strains. Compounds 37a (SQ641) and 38 along with 36b were tested in vivo in a 
murine lung model of tuberculosis.102 These compounds were administered 
intranasally at concentrations of 0.1 or 1 mg per mouse per day for 12 days. The 
mycobacterial load in the lungs was significantly lower in all treated groups when 
compared to that of the untreated controls, demonstrating the strong potential of 
capuramycin analogues as anti-tuberculosis agents. The in vitro screening of 
compound 37a was also extended to a broader spectrum of Mycobacteria sp. 103, 104 In 
these studies 37a demonstrated exceptional anti-mycobacterial activity both alone and 
in combination with other approved anti-tuberculosis agents. Despite the remarkable 
in vitro potency against M. tuberculosis, 37a had low solubility in water. Hence, 
studies were addressed at developing new delivery vehicles and routes of delivery, 
which led to significant improvements in in vivo activity.105 It is also noteworthy that 
further acylation of two hydroxyl groups on the sugar moiety of 37a with amino 
undecanoic acid such as in derivatives 37e-g expanded the in vitro activity of this 
compound against Gram-negative and Gram-positive bacteria (Staphylococci and 
Bacilli), and also improved the activity against Mycobacteria sp.106 Recently, 37a 
demonstrated efficacy in the treatment of C. difficile in a murine model of 
infection.107 
Capuramycin 36a and its analogs 36b-e, 37a-g, 38 are strong translocase I inhibitors 
that are capable of killing only replicating mycobacteria under aerobic conditions. 
However, during a screening of new capuramycin analogs against replicating and 
dormant M. tuberculosis strains, it was found that the 2'-methylated capuramycin 
analog 39 (UT-01320) was able to kill both replicating and non-replicating 
bacteria.108 Interestingly, this compound did not exhibit MraY enzyme inhibitory 
  33 
activity even at high concentrations, but it was instead responsible for the inhibition 
of bacterial RNA polymerases with IC50 values between 100 and 150   nM. In 
addition, this derivative had a synergistic effect with MraY inhibitor 37a, significantly 
improving the in vitro anti-mycobacterial activity.108 Although the exact mechanism 
of action of 39 is still under investigation, this analogue contains a new 
pharmacophore that inhibits the polymerization of bacterial RNA at low 
concentrations in a dose–dependent manner and for this reason deserves further 
attention. 
 
Figure 22. Structured of capuramycin analogues 36a-h; 37a-g; 39. 
 
Antibiotic analogues similar to 36b were discovered in the culture broth of S. griseus 
SANK 60196.109-111 The most active compounds were 40a (A-500359M-1) and 40b 
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(A-500359M-2) (Figure 23). These analogues inhibit MraY with IC50 values of 0.010 
μM and 0.058 μM, respectively. Compound 40a showed activity similar to 36b 
against Mycobacterium sp, whereas 40b showed a broader antibacterial spectrum.110  
A new derivative of capuramycin 41 (A-102395) bearing a benzene ring with a 
substituted chain instead of the aminocaprolactam moiety, was isolated from the 
culture broth of Amycolatopsis sp. SANK 60206 (Figure 23).112  
Although being a potent inhibitor of MraY (IC50 = 11 nM), this analogue did not have 
any antimicrobial activity against various bacterial strains tested. This was suggested 
to be due to poor permeability through the bacterial membrane.  
 
Figure 23. Structures of alternative capuramycin analogues 40a, 40b and 41. 
 
In 2002 scientist at Wyeth in New York isolated a new family of antibiotics called 
muraymycins as complex of nineteen compounds from Streptomyces sp.113 The core 
structure of these compounds consists of the uronic acid (A) connected to a 2-
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methoxy-5-amino-5-deoxy-ribofuranoside (B) and to a 3-aminopropyl residue (C) 
that is juxtaposed to a hydroxy-leucyl residue (D). An unusual feature of the molecule 
is the presence of a hexahydro-2-imino-4-pyrimidylglycyl moiety (E) and a cyclic 
guanidino amino acid residue. The muraymycins terminate in a basic amino acid-
urea-amino acid motif (F) effectively reversing the directionality of the peptide chain. 
Members of the muraymycin family consist of a common peptide-appended 
glycosylated uronic acid core and differ primarily in the fatty acid (R) and the 
terminal amino sugar (B). Compound 42a (Muraymycin A1) was one of the most 
active members of the series, showing in vitro antibacterial activity with MIC values 
ranging from 2 to 16 μg/ml against Staphylococci, 16 to >64 μg/ml against 
Enterococci and 8 to >64 μg/ml against Gram-negative bacteria.113 Potent 
antibacterial activity for 42a was also evident against a mutant strain of E. coli (MIC 
< 0.03 μg/ml), which has a reduced lipid bilayer, hence suggesting that membrane 
permeability plays a key role in the in vivo activity. Compound 42a also demonstrated 
efficacy in S. aureus infected mice (ED50 1.1 mg/ kg).113 The presence and the 
structure of the fatty acid (R) was found to influence activity. Compound 42b, lacking 
of the R chain, although was showing a good enzyme inhibitory activity and no 
apparent toxicity did not demonstrate a good antimicrobial activity. This result 
suggested that the lipophilic 13-hydroxyguanidino lauroyl group (R), positioned on 
the hydroxyl group of the hydroxy leucyl moiety, may be responsible for transporting 
the compound to the target enzyme in the membrane, and at the same time may also 
be responsible for its toxicity. 
In order to improve the activity and the therapeutic index, scientist at Wyeth 
investigated semi-synthetic modification of 42b, having lipophilic groups onto the 
primary amino group of the amino ribose moiety (structures not shown) and/or a 
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secondary amino group at the 15-position of muraymycin (Figure 24).114 Among 
these analogues compounds 43a and 43b, have shown similar inhibitory activity 
against MraY compared to the parent compound (IC50 = 6.25 μg/mL).  
 
 
 
Figure 24. Structures of natural 42a and 42b and synthetic muraymycin analogues 43a and 43b.  
Other synthetic analogues of the muraymycins have also been investigated.115 Among 
these compounds the cyclic guanidine amino acid (E), the 5’-amino ribose sugar 
moiety (B) and the lipophilic side chain (R) were removed.  Surprisingly, compounds 
with a fully protected uridyl moiety 44a-d (Figure 25), showed improved antibacterial 
activity. Among truncated muraymycins compound 44a had activities with MIC 
values ranging from 4 to 16 μg/mL against Staphylococci and from 4 to 8 μg/mL 
against Enterococci, whereas compound 44b showed MIC values ranging from 1 to 2 
μg/mL against the same microorganisms (Figure 25).115 
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Analogues of compounds 44a and 44b with 5’-epimeric hydroxyl group (compounds 
44c and 44d, Figure 25), showed similar activities on Gram-positive bacteria.116 
Muraymycin analogues with a lipophilic substituent 45b-g (Figure 25) were 
synthesized and displayed good activity against a range of Gram-positive bacterial 
pathogens including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant 
E. faecium, without exhibiting significant cytotoxicity against human hepatoceller 
liver carcinoma (HepG2) cells (IC50 > 100 μg/mL).117 The most active compound was 
45b with MIC values ranging from 2 to 4 μg/mL and from 0.25 to 4 μg/mL against 
Staphylococci and Enterococci respectively. The long lipophilic side chain in 
compound 45b is able to influence the antibacterial activity by modulating the 
membrane permeability without jeopardizing the affinity for the target enzyme MraY 
(IC50 = 0.74 M).  Interestingly, analogues with the “natural” stereochemistry are in 
general slightly more potent than those with “unnatural” stereochemistry, although 
45b endowed with unnatural stereochemistry proved to be superior to 45e. The same 
research team investigated the mechanism of action of the most promising analogues 
45b and 45e, and found that they act as inhibitors of MraY with competitive 
inhibition towards the nucleotide substrate and non-competitive inhibition towards the 
lipid substrate.118 
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Figure 25. Active truncated muraymycin analogues 44a-d; 45a-g. 
 
Further investigations were carried out on the scaffold of the lipophilic analogue 45b 
(Figure 25), on which the urea-peptide moiety was modified. These analogues 46a-g 
(Figure 26) retained good inhibitory activity against resistant Staphylococci and 
Enterococci strains (MICs = 1-8 μg/mL).118 
Other derivatives having a lactam-fused isoxazolidine core showed moderate 
antimicrobial activity 47a-g, (Figure 26), with MIC values between 8 and 32 μg/mL 
against Staphylococci and Enterococci.119 
In order to expand the antibacterial spectrum of muraymycins toward P. aeruginosa, 
(a common nosocomial pathogen intrinsically resistant to a variety of drugs currently 
used in the clinic), a systematic  structure−activity relationship study was carried 
out.120 From these investigations it was discovered that both the lipophilic side chain 
and the guanidinium groups are functional groups important for the anti-pseudomonas 
activity. The most active compounds were 48a and 48b (Figure 26) with MIC values 
ranging from 4 to 16 μg/mL against different strains of P. aeruginosa. Some insights 
into the mechanism of action of these analogues and other MraY inhibitors were 
published in 2014.121  
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Muraymycin derivatives lacking of the aminoribose unit were also synthesised. 122  
The 5’-defunctionalized compound 49 was found to be ideal in terms of stability and 
chemical accessibility (Figure 26). This analogue showed good inhibitory properties 
towards the bacterial target protein MraY (IC50 = 1.7 M). Analogue 49 also 
demonstrated sufficient pharmacokinetic stability and no cytotoxicity against human 
cells (up to 100 M), thus making it a promising lead for antibacterial drug 
development. Studies regarding the mechanism of action of muraymycins were 
carried out: the highly unusual ω-guanidinylated fatty acid moiety was proposed to 
mediate membrane penetration, thus enabling the interaction of muraymycins with 
their intracellular target MraY.123 
 
Figure 26. Structures of synthetic muraymycin analogues 46a-g; 47a-f; 48a-b; 49. 
In 2011, Walsh reviewed the biosynthetic pathways for peptidyl nucleosides 
antibiotics with particular focus on the chemical logic and enzymatic machinery for 
uridine transformation and coupling to peptides.124 
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Recently Calvet-Vitale and Gravier-Pellettier reported the synthesis and biological 
evaluation of novel MraY inhibitors. These compounds presented a simplified 
structure still based on the aminoribosyl-O-uridine scaffold, commonly shared 
between liposidomycin, caprazamycins and other natural MuraY inhibitors.125, 126The 
first series of compounds contained a triazole ring directly attached via carbon-carbon 
bond to the 5’ position of the nucleoside, whereas the second series presented an extra 
methylene between the nucleoside and the heteroaromatic ring, which was linked via 
its N- or C atoms to the aminoribosyl-O-uridine. The latest compounds were designed 
to be more flexible thanks to the extra methylene group. The biological activity of 
both series was evaluated on the MraY transferase activity as well as on their 
antimicrobial effects against some common bacteria. Out of thirty compounds tested, 
eighteen compounds had MraY inhibition with IC50 ranging from 15 to 150 μM. In 
general compounds lacking the “extra” methylene unit were found to be less active 
that the “methylene spaced” analogues. Among the compounds of the second series 
the C- connected were found slightly superior to the N-linked analogues. The best 
MraYb inhibitory activities (15-100 µM) were observed with compounds 51a-d and 
52a-d, having a hydrophobic chain on the triazole unit. Promising antibacterial 
activity against MRSA was also observed for compounds 50c and 51c (MIC = 8 
µg/mL) (Figure 27). Generally, the hydrophobic character of the chain and the 
flexible nature of the triazole unit were the key structural motifs to maintain the 
enzyme inhibition activity. A molecular modeling study was performed to rationalize 
the observed structure–activity relationships (SAR), and this allowed the authors to 
correlate the activity of the most potent compounds with their interaction with Leu191 
of MraYAA. 
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Figure 27. Structures of triazole derivatized aminoribosyl-O-uridine antibiotics 50a-d, 51a-d and 52a-
d. 
 
Another particularly important target in peptidoglycan synthesis is the enzyme MurA 
and this has also been targeted by nucleoside analogues.  Showdomycin (51, Figure 
28) isolated from S. showdoensis, is a potent C-glycosyl nucleoside antibiotic, which 
is active against both Gram-positive and Gram-negative bacteria and is especially 
active against S. hemolyticus and S. pyogenes.127 It displays a high structural 
similarity to uridine and pseudo-uridine, with the exception that the bases are replaced 
by an electrophilic maleimide moiety (A).128 It was therefore speculated that nature 
designed this nucleoside analogue may have evolved as a suicide inhibitor that 
interferes with the uridine metabolism. Recent studies indicate that the antibiotic 
effect of showdomycin 51 against S. aureus may be due to the inhibition of various 
essential enzymes, such as MurA, which is required for cell wall biosynthesis.129  
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Figure 28. Structure of Showdomycin (51). 
Chitin synthase inhibitors  
The first chitin synthase (CS) inhibitors were isolated in 1960s from S. Cacaoi var 
asoensis as a result of a screening program for antibiotics active against 
phytopathogenic fungi.130 Structurally, they are uridine-based nucleoside-peptide 
antibiotic constituted by a pyrimidine base (A), and a ribose sugar (B) to which an 
oligopeptide moiety (C) is attached.131 These compounds were called polyoxin B, D, 
L and C (52a-c) and were found to be especially useful as agriculture fungicides. 
(Figure 29) Later on, in 1976, from the fermentation broth of S. tendae a new class of 
antibiotic structurally related to polyoxin were isolated and named Nikkomycin X 
(53a) and Nikkomycin Z (53b) (Figure 29).132, 133  
As CS inhibitors these compounds exhibited a wide spectrum of activities against 
fungi, whilst they are harmless to plants and human since they do not have the target 
enzyme. The ability of nikkomycins and polyoxins to block the CS is due to their 
structural similarity to the natural substrate of this enzyme, the uridine-diphosphate-
N-acetylglucosamine (UDP-GlcNAc).134 In particular, polyoxin B (52a) was reported 
to inhibit CS with an IC50 value of 0.8 g/mL, whereas 53a and 53b inhibits CS with 
IC50 values of 0.1 and 0.3 g/mL respectively. In whole cell assay against two wild 
type strains of C. albicans MIC values for 52b were ranging from 40-20 mg/mL. In 
the same assay MIC values for 53a and 53b were in the range of 5-2.5g/mL and 10-
20 g/mL respectively.135 
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Figure 29. Example of structures of polyoxins 52a-c and nikkomycins 53a-b. 
A common characteristic of antifungals targeting cell wall formation is the fact that 
although these molecules often show excellent in vitro enzyme inhibition their 
success is not reflected in in vivo applications. This in vivo failure is thought to be due 
to poor intracellular uptake, different susceptibility of fungal species, and variable 
responses in animal models.136 
These facts prompted diverse structure-activity-relationship studies in order to 
identify more bioavailable antifungal agents. Polyoxins and nikkomycins enter the 
fungal cell via a dipeptide transport pathway. 137 Considerable research has been 
conducted to replace the amino terminal peptide moiety of polyoxins and 
nikkomycins producing analogues with better ability to penetrate the cell wall.133 To 
prepare these derivatives (Figure 30), compound 54 (uracil polyoxin C) the common 
precursor for both nikkomycins and polyoxins was used. It can be obtained either by 
degradation of polyoxins138 or via multistep synthesis, although this results in low 
yields.139  
To implement the uptake of peptidyl nucleoside Naider and colleagues prepared and 
evaluated several polyoxin and nikkomycin analogues for their antifungal activity and 
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CS inhibition, in which the terminal amino acid was replaced with a di- or tripeptide 
residue.140 The dipeptidyl compounds, were designed to behave as double-targeted 
drugs: being themselves active and releasing a toxic amino acid e.g. oxalysine and m-
fluorophenylalanine. Unfortunately the dipetidyl compounds proved to be inactive 
against C. albicans due to either resistance to the pathogen peptidases or to the poor 
recognition by the peptide transport system.  Among all the tripeptide derivatives, 
designed to behave as prodrugs, only 55a transported into the pathogen and 
hydrolysed to the active compound 53a. However, neither 55a (MIC 83-166 g/mL) 
nor any of the other compounds in the series were more effective than nikkomycin X 
when tested in vitro against C. albicans. The low effectiveness of 55a was suggested 
to be due to its low affinity for the dipeptide transport system, indicating that the 
structural specificity for such transporter is quite complex. 
In search for more potent CS inhibitors the Obi group synthesised a series of 
simplified nikkomycin derivatives having a variety of substituents at the terminal 
amino acid moiety.141, 142 Among twenty derivatives the authors were able to show 
that the analogue 55b lacking of the methyl and –hydroxyl groups and bearing a 
phenanthrene moiety (Figure 30), was a slightly more potent CS inhibitor (IC50 = 0.31 
g/mL) than 53b (IC50 = 0.39 g/mL). It is interesting to note that two chiral centres 
in 53b can be removed without losing any potency in the inhibition of the enzyme, 
and with beneficial simplification of the synthetic method.142 
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Figure 30. Polyoxin C (54), tripeptide nikkomycin X analogue (55a) and nikkomycin Z analogue 
(55b). 
 
In 2003, novel heteroaryl nucleosides derivatives (as model CS inhibitors) appeared 
in the literature.143 The intent of the authors was to modify the UDP-GlcNAc by 
replacing the glucopyranosyl moiety (A) with a heteroaromatic ring (in red) and the 
pyrophosphate moiety (B) with either malonic or tartaric acid scaffolds as well as a 
carbohydrate linkage (in blue). Compounds with these three structural motifs (56a-f) 
were designed to mimic the six membered ring pyrophosphate-Mg2+ complex (in 
purple) that is formed in the active site of the enzyme (Figure 31).144  
 
Figure 31. Hetaryl-nucleoside derivatives as CS inhibitors 56a-f. 
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All compounds displayed weak CS inhibition with IC50 values ranging from 0.8 to 11 
mM. Among these structures only compound 56e showed 80 % growth inhibition of 
C. neoformans and 30 % inhibition of C. albicans, S. cerevisiae and A. fumigatus at a 
concentration of 256 µg/mL. 
The poor activity of these compounds can be explained by the fact that the mode of 
action of CS was not completely understood at the time the experiments were 
conducted. Crucially, it was not known that CS could bind two oppositely orientated 
GlcNAc units. This CS property may explain why attempts to inhibit the enzyme’s 
catalytic activity with a single UDPGlcNAc analogue, are mostly inefficient. In order 
to perform this kind of polymerization, it has been postulated that the enzyme should 
have at least two active sites in the right spatial conformation and at the right distance. 
However, this theory has been opposed by some authors, based on experimental 
evidence gathered from proteins sequence analysis, and crystal structure of single-
sugar glycosyl transferases.145 In 2003, an excellent paper reviewing the CS as an 
antifungal target was also published.146  
In 2004 the Finney group presented the first chemical evaluation of a two-active site 
mechanism for CS and provided evidence that supports this mechanism. Dimeric 
nucleoside analogues 57a-d with different ethylene glycol spacer lengths (A),147 were 
synthetized along with the monomeric control 58a (Figure 32). The basis of this 
design was that if two active sites are close together, a dimeric substrate with the 
appropriate spacer length should be able to simultaneously bind and inhibit both sites, 
hence achieving a more potent antifungal activity. Among all derivatives, those with 
shorter spacer 57a (n = 1) and 57b (n = 2) exhibited the highest inhibition of CS at 1 
mM concentration (32 and 45 % respectively). On the other hand, the monomeric 
control 58a and compounds with longer spacers 57d-e showed poor activity at the 
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same concentrations. At 2 mM concentration 58b did not lead to a more potent 
inhibition of CS, which demonstrates that the greater inhibition of the dimers 57a and 
57b is not simply due to a “double concentration” of the uridine moiety. 
 
Figure 32. Dimeric nucleosides 57a-d and monomeric nucleoside 58a as probes for the CS mechanism. 
 
Dose response analyses showed an IC50 value of 2.2 mM for 57a, 1.1 mM for 57b and 
11.8 mM for 58a. The authors also proved that the inhibition by the dimer 57a (n = 1) 
was competitive. The results combined were supportive for the two-active site model 
for the CS. Although the CS inhibition by 57b was an order of magnitude more potent 
than the corresponding monomer 58a, 57b was still a much weaker CS inhibitor than 
polyoxins and nikkomycins. Thus, with the aim to identify more potent CS inhibitors, 
a second generation of dimeric compounds was investigated by the same group.148 
These new analogues 59a-c and their corresponding monomeric compounds 60a and 
60b displayed as spacer tartaric acid amides (A), which could potentially mimic the 
pyrophosphate group (Figure 33). Monomers 60a and 60b showed greater inhibition 
(12 % and 20 % respectively at 1 mM concentration) when compared with their 
analogue having the ethylene glycol as spacer 58a (6 % at 1 mM concentration). In 
the dimeric series 59a-c, as in the ethylene glycol series, the increase in the 
hydrocarbon spacer length corresponded to a diminished inhibitory activity of the 
molecules with compounds 59a (n = 1) and 59b (n = 2) showing 5 and 10 % 
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inhibition respectively at 1mM. Compounds 59b (n = 3) and 59c (n = 4) were totally 
inactive at the same concentration.  In the same studies along with these compounds a 
short dimer 61 and its monomeric control 62 were also prepared and evaluated as CS 
inhibitors.148 The most active compound was compound 61 with 35 % enzyme 
inhibition at 1mM. Monomer control 62 had reduced activity when compared with 
compound 60b, suggesting that the methyl ether is detrimental for the inhibitory 
activity (Figure 33). 
 
Figure 33. Tartaric amide derivatives 59a-c, 60a,b, 61, 62. 
 
These results supported the “double active site” theory and suggest that the inter-
uridine distance (optimal distance of 12-14 Å) is the primary factor for the inhibitory 
activity of these compounds. The data also appear to demonstrate that the nature of 
the spacer between the two-nucleoside units (as pyrophosphate mimic) does not 
significantly alter enzyme inhibition. 148 
As a part of a research program directed to the identification of novel peptidyl 
antibiotics, based on nikkomycin scaffold, Dutta and colleagues investigated the 
effect of the carbohydrate ring size on their biological activity.149 It was found that 
nikkomycin analogue 63 with an increased ring size, such as a pyranose ring (A), led 
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to an improvement in activity against different human pathogenic fungi (Figure 34). 
In particular, compound 63 was found to be more potent against Coccidioides immitis 
(MIC = 0.03 g/mL) than 53b (MIC = 0.25 g/mL), and was equipotent against C. 
neoformans (MIC = 0.03 g/mL).144  
Encouraged by this result and by Naider investigations,140 Dutta’s group decided to 
further transform compound 63, introducing as consecutive key modification a di- and 
tri-peptide chain into its scaffold.150 The intent was to increase the permeability 
through the fungal cell of this derivative (63), by introducing lipophilic amino acids 
such as leucine, methionine, phenylalanine and tyrosine with the aim of making 63a 
better substrate for the fungal peptidyl transport system. 
The antifungal activity of the double modified compounds 64a-d (Figure 34) was 
evaluated against several fungal species.149 In general the activity profile of these 
novel analogues was found to be very similar to that of compound 63. None of the 
newly designed compounds were active against Candida and Aspergillus strains, 
whereas all the compounds were more potent (MIC = 0.03 µg/mL) than Nikkomycin 
Z (MIC = 0.25 µg/mL) when tested against Cryptococcus and Coccidiosis fungal 
strains. 
Cryptococcus and Coccidioides are responsible for serious human infections of lungs, 
brain and bones, so the results obtained with compounds 64a-d suggested significant 
therapeutic potential. The findings were particularly impressive if compared to the 
current standard treatment amphotericin B whose MIC was 0.25 µg/mL. 
Unfortunately, in vivo results for these derivatives have not yet been reported.  
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Figure 34. Structures of peptidyl-pyranosyl nucleoside analogues 63 and 64a-d. 
 
With the aim of increasing the amount of nikkomycins obtained from biological 
sources (S. ansochromogens), Tan and co-workers151 used recombinant technology to 
manipulate the S. ansochromogens nikkomycins biosynthetic gene cluster by 
introducing a modified plasmid (pNIK) into the bacteria. This resulted in a 4-fold 
(880 mg/L against 220 mg/L in non modified strain) increased production of 53a and 
1.8-fold (210 vs. 120 mg/L) increased synthesis of 53b. The same authors then 
generated two hybrid antibiotics, via a combinatorial biosynthetic approach. The gene 
cluster responsible for the synthesis of the dipeptide moiety of polyoxins was inserted 
into a mutant strain of S. ansochromogens (saN) that responsible for the formation 
of the nucleoside moiety of 53b.152 From the culture broth of this recombinant strain, 
two new hybrid antibiotics named polynik N (65) and polyoxins A (66) were isolated 
(Figure 35). These novel compounds contained the nucleoside core (A) from 53a 
functionalized with the dipeptide chain (B) from 65 and with its 3’’-dehydro analogue  
(C) for compound 66 (Figure 35). 
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Figure 35. Stucture sof polynik A (65) and polyoxin N (66). 
 
65 was a naturally existing nucleoside that had been previously isolated and 
identified, however, 66 was a novel compound, whose structure was unreported. With 
the nucleoside moiety from 53a, the antifungal activities of these two hybrids (MIC = 
2-10 µg/ml) against various microorganisms were generally higher than those of 52a 
(MIC = 10-50 µg/ml). Their activity was lower than those of 53a (MIC = 0.5-10 
µg/ml), though when combined with the peptidyl moiety from polyoxin, 65 and 66 
demonstrated greater stability than 53a.152 Compared to 52a, which had weak 
inhibitory activity against the human pathogen C. albicans (MIC = 50 µg/ml), both 65 
and 66 showed strong inhibitory activity (MIC= 6 µg/ml for both compounds), similar 
to that of 53a (MIC = 2 µg/ml).152 
These results clearly demonstrated the potential of generating new peptidyl 
nucleosides antibiotics with improved properties by simple genetic manipulation of an 
appropriate bacterial strain. 
The same group expanded the diversity of polyoxins structures by a combinatorial 
biosynthetic strategy: transferring the gene responsible for the synthesis of polyoxins 
in S. cacaoi, via pPOL plasmid, into the chromosome of the sanN-mutated strain of 
S. ansochromogens. From the mutated bacteria culture media, two novel antibiotics 
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named polyoxin P (67) and polyoxin O (68) (Figure 36) were obtained along with 
several other known polyoxins.153 
Characterization of the structure of 67 and 68 by high-resolution mass spectrometry 
(MS) and nuclear magnetic resonance (NMR) spectroscopy indicated that the 67 is 
characterized by a thymidine portion (A) and a dehydroxyl-carbamoylpolyoxamic 
acid as peptidyl moiety (B). Compound 68 instead, contains 5-aminohexuronic acid 
with N-glycosically bound thymine (C) and polyoximic acid (D) as the nucleoside 
and the peptidyl moieties respectively. 
 
Figure 36. Structure of novel Polyoxin P (67) and Polyoxin O (68). 
Of the two newly produced compounds, 67 was endowed with the best antifungal 
activity while 68 showed a very weak activity thus indicating that components 
containing different peptidyl moieties posses different biological activity.  
Following the same approach, mutations of industrial S. aureochromogenes YB172 (a 
polyoxins producer) were accomplished by introducing a modified nikkomycin gene 
cluster from S. tendae, resulting in the production of four polyoxin–nikkomycins 
hybrids: the already known polyoxin 66, (Figure 35) and the novel nikkoxin B–D (69-
71).154 The structures of these hybrid antibiotics, elucidated by high-resolution MS 
and NMR analysis, are reported in Figure 37. Compounds 66 and 71 were 
significantly more potent against some human or plant fungal pathogens compared to 
their parent structures (Table 1). 
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Figure 37. Structures of polyoxin–nikkomycins hybrids 69-72. 
 
 Natural antibiotic Hybrid antibiotic* 
Fungal  
Strain 
Nikk Z 
53a 
Nikk X 
53b 
PolA 
72 
PolB 
52a 
PolN 
66 
Nikox B 
69 
Nikox C 
70 
Nikox D 
71 
C. albicans 16 8 > 256 256 16 > 256 > 256 > 256 
T. cutaneum 64 64 64 > 256 256 2 32 0.5 
Table 1 MIC (µg/mL) for natural (3a-b, 72 and hybrid Pol-Nikk antibiotics 66, 69-71; * Pol: 
polyoxins; Nikk: nikkomycins; Nikox: nikkoxin hybrids. 
 
Tan’s group recently synthesised two additional novel nikkomycins structures by 
feeding mutated S. ansochromogens sanL with nicotinic acid.155 The structures of 
these two novel nikkomycin analogues named as nikkomycin Pz (72) and nikkomycin 
Px (73) were identified by high-resolution MS and NMR (Figure 38).  In particular, 
compound 72 was found to have a nucleoside moiety (A) identical to that of 53a, but 
with a 4-(3’-pyridinyl)-homothreonine as peptidyl moiety (B). For 73, the same 
  54 
analyses confirmed the presence of an identical peptidyl moiety (B) as in nikkomycin 
Pz (72) but with the 4-formyl-4-imidazoline-2-one as nucleobase (C). 
Against C. albicans and Achnanthes longipes, compounds 72 and 73 showed 
antifungal activities comparable to nikkomycins 53a and 53b. These results indicated 
that the incorporation of the nicotinic acid has no effect on the biological activity of 
these drugs. However, 72 and 73
 
were found to have an increased
 
stability under 
different temperature ranges as well as at different pHs, reinforcing the idea that the 
peptidyl moiety is able to influence the stability of these classes of compounds. 
 
Figure 38. Structures of Nikkomycin Px (72) and Nikkomycin Pz (73).  
 
The search for novel antibiotics led to the replacement of the peptide bond of 
nikkomycin with a triazole moiety.156 The 1,2,3-triazole unit acts as surrogate of the 
peptide bond, both in terms of atom placement and electronic properties.  
Two sets of novel 1,2,3-triazolyl linked uridine derivatives were prepared with either 
an aryl ester or ether as substituent on the 1,2,3-triazole ring. Several of the 
synthesised structures were found to be active against C. albicans and C. neoformans 
(MICs = 8-64 g/mL). Compound 74a (Figure 39) was the most potent against C. 
neoformans with a MIC value of 8 µg/mL, whereas compound 74b and 74c were the 
most potent compounds against C. albicans (MIC = 24 g/mL) and F. oxysporum 
(MIC = 32 g/mL) respectively. A very interesting review of the synthesis and the 
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subsequent biological evaluation of both polyoxins and nikkomycins has been also 
published.157  
Wandzik and co-workers designed, and evaluated as antifungal agents, a series of 5’-
uridine nucleoside analogues 75a-c.These analogues contained a keto-enolic motif158 
able to mimic the phosphate unit, that is involved in the essential Mg2+ coordination 
in the active site of CS and other glycosyl transferases (Figure 39). Unfortunately, 
none of these compounds showed activity against C. albicans or A. fumigatus up to 
1,000 µg/mL concentration. 
 
 
Figure 39. Structures of triazole derivatives 74a-c, and 5’-uridine nucleoside analogues 75a-c. 
Some other natural peptydil nucleosides, such as ezomycin159-161 ampipurimycin162-166 
and miharamycins,167-170 also exhibit potent antifungal activities against a broad range 
of fungi species. The exact modes of action of these compounds have yet to be 
defined however, the synthetic “medicinal” chemical studies make these nucleosides 
potentially attractive new antifungal agents, worthy of further investigation. In this 
regard, the total synthesis of complex nucleosides antibiotics has been reviewed by 
Knapp.171 
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Nucleoside antibiotic that interfere with nucleotide metabolism. 
Nucleotide biosynthesis is crucial for all living organisms and therefore also for the 
growth of bacteria. The metabolic requirements for the nucleotides in bacteria can be 
met either by a salvage pathway from low molecular weight precursors or by de novo 
synthesis. 
The salvage pathway of both purines and pyrimidines represents an energy-efficient 
way to produce the building blocks of DNA and RNA, but depends on the availability 
of nutrients. During bacterial proliferation in the blood stream, it was shown that de 
novo biosynthesis of pyrimidine and purine nucleosides is crucial for the growth of 
several virulent E. coli strains and for S. enterica and B. antracis. These findings were 
ascribed to the limited availability of the nucleosides in the blood.172 Enzymes 
involved either in the de novo or salvage pathways are critical for the survival and 
proliferation of pathogenic bacteria and are therefore potential targets for the 
treatment of these infections. 
 
Phosphoribosyltransferase inhibitors 
Phosphoribosyl transferases (PRTs) are enzymes involved in the purine salvage 
pathway and are essential for the reproduction and survival of different pathogens. 
Within this family, hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and 
xanthine-guanine phosphoribosyltransferase (XGPRT) were identified as interesting 
targets for the development of new anti-bacterial agents.173, 174  
HGPRT catalyses the Mg2+-dependent reversible transfers of the 5-phosphorybosyl 
group from 5-phosphoribose-1-pyrophosphate (PRPP) to the N9 position of 6-
oxopurines (H and G), to form inosine monophosphate (IMP) and guanosine 
monophosphate (GMP) respectively, with concomitant release of inorganic 
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pyrophosphate (PPi) (Figure 40). XGPRT catalyses the same transfer to xanthine, 
guanine and (to a lesser extent) hypoxanthine to form XMP (xanthosine 
monophosphate), GMP, and IMP, respectively. 
 
Figure 40. Enzymatic reaction catalyzed by hypoxanthine-guanine phosphorybosyl transferase. H = 
hypoxanthine, G = guanine, PRPP = 5-phosphoribose-1-pyrophosphate, HGPRT = hypoxanthine-
guanine phosphoribosyltransferase, IMP = inosine monophosphate, GMP = guanosine monophosphate, 
PPi = inorganic pyrophosphate. 
 
Mammalian cells have two different pathways for the synthesis of the essential 6-
oxopurine nucleosides monophosphates: the de novo (from small molecules) and 
salvage (of purine bases) pathways. However, clinically important bacteria such as 
e.g. M. tuberculosis and H. pylori do not possess the necessary enzymes for the de 
novo synthesis and rely exclusively on the transport of preformed purine bases from 
the host cell.175, 176 These differences in metabolism between infectious agents and 
their host cells can be exploited in the design of drugs aimed at fighting these 
pathogens. As these organisms have only one pathway for the synthesis of the purine 
nucleoside mono- phosphates needed for DNA/RNA production, they depend on the 
activity of their 6-oxopurine PRTases for both reproduction and survival. Acyclic 
nucleoside phosphonates containing a second phosphonate group have been identified 
as potent inhibitors of 6-oxopurine phosphoribosyl transferases.177 Keough et al. 
reported a number of novel acyclic nucleoside phosphonates inhibitors of XGPRT and 
HGPRT from E. coli with Ki values as low as 10 nM.178 These acyclic nucleoside 
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phosphonates were also inhibitors of mycobacterial HGPRT, with Ki values as low as 
0.69 M.179 Prodrugs of these compounds were shown to arrest the growth of a 
virulent strain of M. tuberculosis in cell-based assays with MIC values as low as 4.5 
M, without significant cytoxicity in mammalian cells (CC50 > 300 M). The 
structure of the most potent compound in the series (76) (IC50 = 5 M against M. 
tuberculosis) is depicted in Figure 41.  
 
Figure 41. Structure of HGPRT inhibitor 76. 
 
Guanosine monophosphate synthase inhibitors 
GMP synthase is an enzyme that converts XMP to GMP in the presence of adenosine 
triphosphate (ATP), glutamine and Mg2+ (Figure 42). GMP synthase has significantly 
diverged across prokaryotes and eukaryotes supporting its consideration as an 
antifungal target.180 
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Figure 42. Enzymatic reaction catalysed by guanosine monophosphate synthase. XMP = xanthosine 
monophosphate; ATP = adenosine triphosphate; AMP = adenosine monophosphate; GMP = guanosine 
monophosphate; PPi = inorganic pyrophosphate. 
 
Oxanosine (77) (Figure 43) is a guanosine analogue, isolated from the culture filtrate 
of a strain of Streptomyces.181 Compound 77 showed weak growth inhibition of E. 
coli K-12 (MIC 12.5 µg/ml). This bacteriostatic activity was due to the inhibition of 
GMP synthase, and was antagonised by guanine, guanosine, and guanylic acid.182 
Psicofuranine (78) (Figure 43) is an adenosine analogue, first described in 1959 when 
it was isolated from culture media of S. hygroscopicus var. decoyinine.183 Since its 
discovery, the structural similarity to the endogenous nucleoside has been linked to an 
antimetabolite mode of action. Compound 78 has been shown to inhibit the amination 
of XMP to GMP catalysed by GMP synthetase in E coli and guanine, guanosine and 
GMP could reverse growth inhibition in psicofuranine treated S. aureus.184 
Mizoribine (79a, Figure 43) is a nucleoside analogue bearing an imidazole nucleobase, 
isolated from the culture medium of the mould E. brefeldianum M-2166.185 Bredinin 
(79b), the monophosphate form of 79a (Figure 43), exerts antibacterial activity 
through selective inhibition of GMP (Ki= 100 M) and IMP synthetases (Ki = 0.1 
M), resulting in the complete inhibition of guanine nucleotide synthesis and arrest of 
DNA synthesis in the S phase of cell division. Although this compound has been 
found to have weak antimicrobial activity against C. albicans, it has proven 
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ineffective against experimental candidiasis, probably due to lack of membrane 
penetration. This compound is mostly used as an immunosuppressive agent due to the 
inhibition of the lymphocyte proliferation.186 
 
Figure 43. Structures of GMP synthase inhibitors 77-78 and 79a,b. 
 
Inosine-5-monophosphate dehydrogenase inhibitors 
 
Inosine-5′-monophosphate dehydrogenase (IMPDH) is a purine biosynthetic enzyme 
that catalyzes the nicotinamide adenine dinucleotide (NAD+)-dependent oxidation of 
IMP to XMP, the first and rate-determining step in the de novo biosynthesis of 
guanine nucleotides from IMP (Figure 44). Bacterial IMPDH enzymes show 
biochemical and kinetic characteristics that are different from the mammalian 
enzymes, suggesting IMPDH may be an attractive target for the development of 
antimicrobial agents. 187 
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Figure 44. Enzymatic reaction catalyzed by inosine monophosphate dehydrogenase. IMP = inosine 
monophosphate; XMP = xanthosine monophosphate; IMPDH = inosine monophosphate 
dehydrogenase; NAD = nicotinamide adenine dinucleotide. 
 
IMPDH is a regulator of the intracellular guanine nucleotide pool, and is therefore 
important for DNA and RNA synthesis, signal transduction, energy transfer and 
glycoprotein synthesis, as well as other processes involved in cellular proliferation. 
Ribavirin (80, Figure 45) discovered in 1972 by Witkowski and coworkers,188 is a 
guanosine analogue mainly used as an antiviral agent. However, 80 has also 
demonstrated antibacterial activity against P. areuginosa (MIC = 3 g/mL). 
Compound 80 exerts its antibacterial activity as 5'-monophosphate by inhibiting the 
cellular inosine monophosphate dehydrogenase, thereby depleting intracellular pools 
of GTP.189 
 
Figure 45. Structure of ribavirin (80). 
Pertussis adenylate cyclase toxin (ACT) 
Pertussis adenylate cyclase toxin (ACT) is a bacterial enzyme considered to be an 
important virulence factor for B. pertussis infection.190 After penetration into the 
human macrophages ACT is activated by endogenous calmodulin and catalyses the 
conversion of ATP into cyclic AMP (cAMP). This causes disruption of host cell 
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functions and facilitates an effective bacterial invasion and colonization of the host 
(Figure 46). 
 
Figure 46. Enzymatic reaction catalysed by Pertussis adenylate cyclase toxin. ATP = adenosine 
triphosphate; ACT = adenylate cyclase toxin; cAMP = cyclic adenosine monophosphate; PPi = 
inorganic pyrophosphate. 
 
Novel C2-modified analogues of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA, 
adefovir) (structure not disclosed), in the form of their bis-amidate prodrugs, were 
found to inhibit the activity of ACT.191 They are capable of crossing the macrophage 
cell membrane and then release PMEA, which is subsequently phosphorylated to 
active PMEA diphosphate, which is in turn able to inhibit the activity of ACT. The 
most active compound of the series was found to be the 2-fluoro PMEA bis-amidate 
prodrug 81 (IC50= 0.145 M) (Figure 47). 
 
Figure 47. Structure of 2-fluoro PMEA derivative 81. 
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Nucleoside antibiotic that inhibit nucleic acid synthesis 
Nucleoside analogues used in the treatment of viral infections and cancer conditions 
have also demonstrated efficacy in inhibiting the synthesis of bacterial nucleic acids. 
It has been shown that these nucleoside drugs could be efficiently converted to their 
active triphosphate form by bacterial deoxynucleoside kinases (dNKs). Such 
nucleoside analogues may therefore have great potential as antibiotics for the 
treatment of bacterial infections, in particular by multi-drug resistant strains. 
Studies on several FDA approved nucleoside analogue drugs, screened for their 
potential bactericidal activity against Gram-positive and Gram-negative bacteria, 
indicated 3’-azido-3’-deoxythymidine (82, AZT; zidovudine), 5-fluoro-2’-
deoxyruridine (83, FdUrd) and 2’,2’-difluoro-2’-deoxycytidine (84, gemcitabine) as 
the most active nucleosides (Figure 48).192, 193 In particular, 84 was found very active 
against Gram-positive bacteria (e.g. MIC values against S. aureus and S. pyogenes 
lower than 0.002 g/mL and 0.2 g/mL, respectively) but inactive against Gram-
negative bacteria, which were instead susceptible to 82 (MIC values against E. coli 
were between 10 M to 31.6 M). Conversely, none of the Gram-positive bacteria 
was susceptible to AZT. 83 was found active towards both Gram-positive and Gram-
negative bacteria; however, the lowest minimal inhibitory concentrations were in the 
range from 0.003 M to 1 M and from 1 M to 10 M respectively for the Gram-
positive and the Gram-negative strains. These results demonstrate a wide variation in 
kinase substrate preferences suggesting that the different nucleoside analogues may 
possess species-specific activity (Figure 48).  
To investigate the potential in vivo efficacy of 84, this compound was evaluated in an 
in vivo mouse model of S. pyogenes infection. 84 was able to protect the treated 
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animal from bacterial spread and systemic infection, demonstrating that nucleoside 
can indeed be used as antibiotics.192 
More lipophilic AZT derivatives have been developed with the aim of improving its 
antiviral and bactericidal activity. Among them, the 5’ leucine AZT prodrug 85 
(Figure 48) was reported to be the most effective antibacterial agent with a MIC value 
of 0.125 g/mL against Klebsiella pneumonaiae.194 
Among other nucleosides affecting the nucleic acid synthesis, Sangivamycin (86), 
(Figure 48) isolated from S. rimosus had poor antibacterial and antifungal activities.195 
The triphosphate form can inhibit bacterial and fungal nucleic acid synthesis and can 
also compete with ATP in various reactions, acting as inhibitor of protein kinases.196 
Blue-green algae have proven to be an excellent source of bioactive compounds. 
Moore and co-workers isolated, from different Scytonemataceae strains, two 
nucleosides with antifungal activity: tubercidin (87) and toyocamycin (88) (Figure 
48).197 Compound 87 is responsible for the antifungal activity of these algae and for 
the antifungal activity of extracts from Scytonema saleyeriense var. indica.198 On the 
other hand, most of the activity of the extract from Plectonema radiosum and 
Tolypothrix distorta was due to the tubercidin 5'--D-glucopyranose derivative 89.198 
Compound 87 serves as a substrate for numerous enzymes involved in the anabolism 
of adenosine, as demonstrated by its incorporation into RNA and DNA, and by the 
formation of nicotinamide-deaza-adenine dinucleotide. Moreover, this analogue 
proved to be a weak inhibitor of adenosine phosphorylase, interfering with the 
phosphorylation of adenosine and AMP.199 
Compound 88  (Figure 48) and toyocamycin 5'--D-glucopyranose 90, the minor and 
major constituent in Tolypothrix tenuis extract, are responsible for the cytotoxic and 
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fungicidal properties of this extract. It was suggested that their mechanism of action is 
linked to the blocking of the ribosomal RNA synthesis. 
 
Figure 48: Structures of nucleic acid inhibitors 82-84, AZT prodrug 85, Sangivamycin (86), Tubercidin  
(87) and toyocamycin (88) and their glucose derivatives (89-90).  
Protein synthesis inhibitors 
Ribosomal peptidyl center inhibitors  
 
Mildiomycin (91, Figure 49) is a nucleoside antibiotic isolated from the culture 
filtrate of S. rimofaciens B-9889 that has shown strong activity against powdery 
mildews on various plants, and remarkably low toxicity in mammals and fishes.200-202 
The mode of action of this antibiotic was linked to the inhibition of protein synthesis 
and to a lesser extent to the DNA synthesis.202 Since it does not affect RNA 
production, the slight inhibition of DNA synthesis observed with this compound can 
be explained by the effect observed on translation. Studies on the mode of action of 
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this nucleoside showed that with 91 present, the binding of the natural substrates to 
the ribosome was unaffected, whereas inhibition of the peptide-bond formation was 
observed. This finding suggested that the target of Mildiomycin action is the peptidyl-
transferase center located on the larger ribosomal subunit.203 
 
Figure 49. Structures of ribosomal peptidyl center inhibitors: Mildiomycin (91), 1,3-Thiazolidines 92a-
b, Hygromycin A (93), A201A (94), Puromycin (95), Blasticidin S (96). 
 
1,3-Thiazolidines pyrimidine nucleosides are a class of antimicrobial agents reported 
by Sriharsha et al., with activity against a broad spectrum of Gram-positive pathogens 
including Staphylococci, Streptococci and Enterococci.204 Among these derivatives, 
compounds bearing bromine and chlorine at the 5 position on the uracil ring 92a,c 
(Figure 49) showed increased activity against all tested bacteria, including Bacitracin-
resistant bacteria. The mode of action of these compounds implies inhibition of the 
protein synthesis in actively growing bacteria by binding to the bacterial 50S 
ribosomal subunit and inhibition of formation of the 70S ribosomal initiation complex, 
eventually blocking bacterial protein synthesis.  
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Hygromycin A (93) and 94 (A201A) (Figure 49) are antibiotics, which have been 
found to inhibit bacterial protein synthesis. Compound 93, first discovered in 1953 as 
a metabolite produced by S. hygroscopicus, has a broad activity mainly against Gram-
positive bacteria.205 94 is an aminoacyl-nucleoside antibiotic that was first isolated 
from S. capreolus NRRL 3817.206 It is active against Gram-positive aerobic and 
anaerobic bacteria and most Gram-negative anaerobic species. 
Both antibiotics inhibit translation by binding the peptidyl transferase center on the 
larger ribosomal subunit, sterically occluding the A site. Despite not impeding the 
binding of tRNA, they prevent its full accommodation in the peptidyl transferase 
center, thereby inhibiting the peptide bond formation.207 
Puromycin (95, Figure 49) is an amino-nucleoside antibiotic derived from the S. 
alboniger, that causes premature chain termination during translation.208 95 contains 
an amide linkage at the 3' position, which resembles the 3' end of the aminoacylated 
tRNA. The amide moiety makes the molecule much more resistant to hydrolysis when 
compared to the normal ester linkage of tRNA. As such, when puromycin enters the 
A site of the ribosome, it is transferred to the RNA growing chain, causing the 
formation of a puromycin-RNA chain and premature chain release. Several analogues 
of puromycin bearing modifications at the sugar and nucleobase levels were prepared, 
but their antibacterial activities were lower than, or in the same range as, 95.209-212 
Blasticidin S (96) is a nucleoside analogue consisting of a cytosine linked to a 
dideoxyhexose and bonded to a modified arginine (Figure 49).213-215 This analogue 
was isolated from the broth of S. griseochromogenes in an effort to identify natural 
non-mercurial fungicides. Compound 96 has been used on a large scale to control rice 
blast by foliar application against Pyricularia oryzae, a virulent fungus that was the 
cause of a serious disease in Asia. Analogue 96 strongly inhibited the production of 
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aflatoxin by A. flavus without impairing fungal growth, and was found to exert its 
inhibitory activity by interfering with ribosomal protein synthesis in host cells. Unlike 
other peptidyl transferase inhibitors that bind to the A site of the large ribosomal 
subunit, such as the clinically used chloramphenicol, linezolid, lincomycin and 
clindamycin, , Blasticidin S occupies the P site, where it induces conformational 
changes of the P-site tRNA.  
Aminoacyl tRNA synthetase inhibitors 
Aminoacyl-tRNA synthetases (aaRSs) play an indispensable role in protein synthesis. 
These proteins aminoacylate tRNAs with cognate amino acids in a two-stage process 
whereby the amino acid is first activated with adenosine monophosphate (AMP) and 
then esterified at the 2’- or 3’-hydroxyl groups of the 3’-end of respective tRNA 
(Figure 50). Taking advantage of the significant differences between prokaryotic and 
eukaryotic aaRSs, selective inhibition of bacterial aaRSs enzymes can be used as drug 
target.216  
 
Figure 50. Aminoacyl-tRNA synthetases mechanism of action. AA = amino acid; ATP = adenosine 
triphosphate; PPi =inorganic pyrophosphate; amino-acyl-AMP = 5’-O-aminoacyl adenosine 
monophosphate; AMP = adenosine monophosphate. 
 
Ascamycin (97a) and dealanylascamycin (97b) isolated in 1982 from Streptomyces 
sp. culture,217 are natural nucleoside antibiotics capable of inhibiting the aaRSs. These 
analogues bear an unusual 5′-O-sulfonamide moiety (A), which is linked to an 
adenosine nucleoside (B) (Figure 51). 97a is active against few microorganisms, such 
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as Xanthomonas. 97b on the other hand shows broad-spectrum inhibitory activity 
against various Gram-positive and -negative bacteria and eukaryotic Trypanosoma, 
but unfortunately it is also toxic to mice. 218 
Natural compounds 97a and 97b, along with amino-acyl adenylate (amino-acyl 
AMP), an intermediate in the enzymatic reaction, have been used as a starting 
prototype to design novel aaRS inhibitors. The amino-acyl AMP is a mixed 
anhydride, which is bound more tightly to the enzyme than amino acid and ATP (the 
two natural substrates). Thus, structural analogues of this mixed anhydride and of the 
natural substrates have been designed to study their interactions with the 
corresponding enzymes. Several diadenosine-5’-tetraphosphate phosphonate 
analogues have been synthesised and proved to be moderate inhibitors of alanyl, lysyl 
and phenyl alanyl tRNA synthetases from E Coli.219 Ester analogues prepared by 
Desjardins et al. were also weak inhibitors of glutamyl tRNA synthetase.220  
In order to elucidate the substrate specificity of alanyl-tRNA synthetase, Ueda et al. 
reported the synthesis and molecular conformation study, by X-ray single crystal 
analysis, of 5'-O-[N-(L-alanyl)sulfamoyl]adenosine (98), an analogue of 97a (Figure 
51).221 This research provided useful insights for analysing the mechanism of specific 
amino acylation. Several other derivatives were successively reported, such as two 
non-hydrolyzable prolyl adenylate analogues 99a (L-PSA) and 99b (D-PSA) (Figure 
51).222 These compounds were structurally related to the natural antibiotic 97a and the 
synthetic derivative 98 reported by Ueda221 (Figure 51). 99a was the most potent 
inhibitor of both human and E. coli prolyl-tRNA synthetases with Ki in the 
subnanomolar to low-nanomolar range (Ki= 0.6 nM for human proline synthetase and 
Ki= 4.3 nM for E. coli prolyn synthetase). 99b was found to be less potent (Ki= 85 
nM for human proline synthetase and Ki = 490nM for E. coli proline synthetase). 
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Since both compounds showed activity against the human isoform of the enzyme, 
they were potentially toxic and therefore unsuitable for clinical antibiotic use. 222 
Cusak’s group reported the crystal structures of seryl-tRNA synthetase from Thermus 
thermophiles, in complex with two different analogues of seryl adenylate: 5'-O-[N-(L-
seryl)-sulfamoyl]adenosine (100a) and seryl-hydroxamate-adenosine monophosphate 
(100b) (Figure 51).223 These studies revealed the region of the enzyme involved in the 
interactions and showed that, apart from the specific recognition of the serine side 
chain, the interactions were similar to the other amino- acyl synthetases. The 
inhibition constant of 100a for the E. coli enzyme was found to be in the nanomolar 
range.223 
Molecular modelling and synthetic studies on tyrosinyl adenylate analogues224 have 
been carried out to probe the interactions seen by Brick et al.225 in the active site of 
tyrosyl tRNA synthetase from B. stearothermophilus. These studies also aimed to find 
new inhibitors of tyrosyl tRNA synthetase. Three specific areas of the adenylate 
interactions were examined: the phosphate moiety, the role of the ribose hydroxyl 
groups, and the specificity of the adenine binding. To this end a variety of inhibitors 
of tyrosyl tRNA synthetase with alterations in these three part of tyrosinyl adenylate 
were synthesized. While it has been found that the level of inhibition of this enzyme 
can be maintained by replacement of the phosphate with the sulfamate moiety, other 
variants were shown to lead to substantially decreased potency. Among different 
derivatives, compounds 101a,b were found to have an inhibitory activity for tyrosyl 
tRNA synthetases from both B. stearothermophilus and S. aureus with IC50 values in 
the micromolar and sub-micromolar ranges respectively (for 101a Ki = 0.011-0.0063 
M; for 101b Ki = 0.026-0.0093 M) (Figure 51). Glutaminyl adenylate analogues 
were also synthesized as inhibitors of glutaminyl-tRNA synthetase.226 Compound 102 
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was found to be a competitive inhibitor of glutaminyl-tRNA synthetase from E. coli 
(Ki=0.28 M) (Figure 51). 
 
Figure 51. Structures of natural nucleoside antibiotics Ascamycin (97a) and Dealanylascamycin (97b) 
and synthetic aatRNAs inhibitors 98-102.  
Subsequently, ester, amide, N-alkyl hydroxamate and O-alkyl hydroxamate methionyl 
adenylate analogues 103a-d were also examined (Figure 52).227 Their relative 
activities as inhibitors of methionyl adenylate synthetase from E. coli were as follows: 
103a (ester) > 103c (N-hydroxamate) > 103b (amide) > 103d (O-hydroxamate). 
Among these compounds the ester analogue 103a was found to be the most potent 
with Ki = 10.9 M. Antibacterial activities of methionyl adenylate 103a-d were 
examined against different bacterial species. The extent of their activities was 
proportionally correlated to the extent of their enzyme inhibition, with 103a showing 
a strong growth inhibition of E. coli (MIC = 0.5 g/mL) and moderate inhibition of B. 
cereus (MIC =32 g/mL). 
Extensive SARs of ester and hydroxamate analogues of methionyl and isoleucyl 
adenylate were carried out by introducing a linker between the nucleobase and the 
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ribose. Adenine and adenine heterocyclic surrogates were linked to ribose by one or 
two carbon units. Among the tested analogues, compound 104 was found the most 
potent inhibitors of methionyl tRNA synthetase (IC50= 3.6 M) from E. coli (Figure 
52).228 
In 2003, a series of sulfamate surrogates of methionyl and isoleucyl adenylate were 
investigated as methionyl and isoleucyl tRNA synthase inhibitors, by modifications of 
both the sulfamate linker and adenine moieties.229 Among this series, the 2-iodo 
analogue 105 emerged as the most potent inhibitor of isoleucyl tRNA synthase from E. 
coli (IC50 = 0.014 M) (Figure 52). Docking studies with the X-ray structure of the 
isoleucyl tRNA synthase from T. Thermophilus indicated that a significant 
hydrophobic interaction between the 2-substituent and the adenine-binding site was 
responsible for the high potency of this compound. No selectivity toward different 
species aaRSs was reported/discussed.  
Several modifications have been attempted in order to improve the inhibitory activity 
and selectivity of these aminoacyl-sulfamoyl adenosine analogues. Among them 2’-
deoxy, 3’-deoxy, and 2’,3’-dideoxyribosyl surrogates of isoleucyl and methionyl 
sulfamate adenylates have been investigated to identify the pharmacophoric 
importance of the ribose group for the inhibition of E. coli methionyl-tRNA and 
isoleucyl-tRNA (IRS) synthetases. Unfortunately, replacement of the ribofuranose 
with 2’- or 3’-deoxy or 2’,3’-dideoxy sugars yielded less potent aaRS inhibitors.230 
Cubist Pharmaceuticals reported the first examples of selective bacterial aaRSs 
inhibitors.216 The structures of the two most interesting compounds 106a (CB168) and 
106b (CB432) are depicted in Figure 52. Although still based upon aminoacyl 
sulfamoyl adenosine scaffold, these analogues contain an aryl-tetrazole in place of the 
adenine moiety, connected via a two-carbon linker to a ribose ring. These analogues 
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exhibited good inhibitory activity against isoleucyl tRNA synthetase from various 
bacteria species but poor inhibition of the human homologue. 106a was found to 
inhibit E coli synthases with a Ki value of 1.3 g/mL while inhibiting the 
corresponding human enzyme with a Ki value of 3000g/mL. 106b showed moderate 
activity against a broad range of bacteria including S. aureus, S. epidermidis, S. 
saprophyticus, S. pneumoniae S. pyogenes, E. faecium, E. faecalis, B. subtilis, 
Haemophilus influenzae, K. pneumoniae, and M. catarrhalis, with MIC values 
ranging between 2 and 100 g/mL. To determine the usefulness of 106b in a model 
therapeutic application, this compound was tested in an in vivo murine model of S. 
pyogenes infections.216 Although the compound was able to increase the animal 
survival, the dose required for its efficacy was too high to be useful for human 
applications. This high dosage was attributed to low bioavailability due to low cell 
permeability and strong binding to serum albumin of 106b. 
In order to address the selectivity issue of the sulfamoylated adenosines, Gadakh et al. 
further investigated the pharmacophoric importance of the adenine base.231 Several 
isoleucyl-sulfamoyl nucleoside analogues were synthesized, bearing uracil, cytosine, 
hypoxanthine, guanine, 1,3-dideaza-adenine (benzimidazole) and 4-nitro-
benzimidazole as the heterocyclic base. From in vitro evaluation, the uracil derivative 
106c showed the best inhibitory activity (Figure 52).  Unfortunately, only weak 
growth inhibitory properties were found for 106c due to its low cellular uptake. 
However, similar results were obtained with the hexapeptidyl (formal-MRTGNA-
OH) conjugate of 106c prepared in the effort to promote its bacterial uptake. 
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Figure 52. Structures of synthetic aatRNAs inhibitors 103-106.  
 
To overcome the poor permeation of aminoacyl-adenylates into bacterial cells, the 
active component that mimic aminoacyl-adenylate intermediates can be conjugated 
with a specialized module that facilitates its active transport into bacterial cell. The 
transport module can be subsequently removed, releasing the inhibitor inside the 
cell.232 Examples of naturally occurring aminoacyl-adenylate-based antibiotics that 
employ this strategy include the aspartyl-tRNA synthetase inhibitor microcin C 
(107a) the seryl-tRNA synthetase inhibitor Albomycin (108) and the leucyl-tRNA 
synthetase inhibitor Agrocin 84 (109) (Figure 53).  
107a is a natural compound produced by Enterobacteriaceae, consisting of an 
adenosine group (A) linked to a heptapeptide (B) through a C-terminal P-N bond (C). 
A propylamine group (D) additionally modifies the phosphoroamidate group of the 
nucleotide part of 107a.233, 234 In vivo, 107a appears to target translation with the 
peptide part responsible for the transport of the antibiotic into the cell, whereas the 
nucleotide part is involved in the translation inhibition. Once inside the cell, this 
compound is metabolised by a peptide deformylase and an aminopeptidase enzyme, 
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which liberate a non-hydrolyzable analogue of aspartyl adenylate 107b. This 
compound is able to inhibit the aspartyl tRNA synthase in E. coli, but is also active 
against the human isoform.235 Acquisition of resistance via acetylation of the 
processed form of the antibiotic and in vivo instability of the peptide chain, are serious 
disadvantages for this drug.236 
108a is another natural aaRS inhibitor, which belongs to the class of siderophore drug 
conjugates (Figure 53). It is composed of an iron carrier linked to an antibiotic 
moiety. The iron carrier is a tripeptide composed of N5-hydroxy-(L)-ornithines (A), 
that mimicks the siderophore ferrichrome. The antibiotic moiety is a 4’-thio-6’-amino 
heptonic acid bearing a modified cytosine attached to the 1’-position (B). The 
siderophore allows albomycin to be taken up by a ferrichrome transport mechanism, 
which is expressed in many bacteria. Once inside the cell, the compound is processed 
with the release of the active moiety 108b, which resembles seryl adenylate and 
therefore inhibits seryl tRNA synthase.237 This analogue is particularly effective 
against Gram-negative bacteria such as Enterobacteriaceae and few Gram-positive 
bacteria like S. pneumoniae, B. subtilis and S. aureus. 
109 is a disubstituted analogue of adenosine produced by Agrobacterium radiobacter 
K84, a non-pathogenic member of the genus isolated in Australia (Figure 53). The 
nucleoside core, which is essential for toxicity, contains 3’-deoxyarabinose (A) 
instead of the common ribose unit. The methyl-substituted pentanamide (B) at the 5’-
position is also required for activity. Although the glucofuranose (C) at the N6 
position  does not confer toxicity it is required for transport inside the bacterium and 
therefore is critical to functionality. Both groups are linked to the nucleoside core by 
phosphoroamidate bonds (D). 109 is an aaRS inhibitor, active only against certain 
  76 
strains of the phytopathogenic agrobacteria such as A. tumefaciens and A. 
rhizogenes.238 
 
Figure 53. Structures of Microcin C (107a), processed Microcin C (107b), Albomycin (108), processed 
form of Albomycin (108b) and Agrocin 84 (109). 
 
In search for bacterial aaRSs inhibitors endowed with in vivo activity, Vondenhoff 
and co-workers reported a series of microcin C 110a-c and albomycin analogues 
111a-b with aryl tetrazole substituents as nucleobase isosters (Figure 54).239 
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Figure 54. Structures of aryl tetrazole microcin C 110a-e and albomycin conjugates 111a-b. 
 
Unfortunately, no antibacterial activity was observed with these new analogues in 
whole-cell assay. These compounds showed strong activity against isoleucyl tRNA 
synthase in E. coli cell extracts. The activity was dependent on processing by cellular 
peptidases. Since all the compounds were efficiently metabolized, the absence of 
antibacterial activity can be attributed only to the lack of cellular uptake. These results 
strongly suggest that not only the siderophore but also the nucleoside portion of these 
analogues are fundamental for the transport inside the bacterial cell. Using the same 
strategy, Gadakh et al. reported a series of sulfamoylated nucleoside analogues 
bearing different nucleobases, coupled with a hexapeptide in the effort to improve 
their uptake.231 However, no significant activity was found for these derivatives. On 
the basis of these results, Vonderhoff et al. turned their attention to another class of 
microcin C analogues with a preserved nucleoside core but with the siderophore 
portion modified with N-methyl or D-amino acids (Figure 55).240 The authors 
believed that these modifications would potentially help to escape the natural 
inactivation mechanism of acetylation of the amino group and/or prevent the in vivo 
instability of the peptide chain. A series of N-methyl and D-aminoacyl, sulfamoyl 
adenosine analogues 112a-d, 113a-e were prepared and investigated as potential 
aaRSs inhibitors. Unfortunately, all N-methylated aaSAs proved to be inactive in 
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whole-cell assays. In addition, these analogues were ineffective as tRNA 
aminoacylation inhibitors in cell extracts. The same result was obtained when the 
amino acid residues in positions 2 to 6 had a D-configuration, indicating that despite 
the better stability, the metabolism by peptidase enzymes was significant, thus 
preventing the release of the active moiety and consequent inhibition of aatRNAs. 
Compounds bearing a D-amino acid in position 1 of the peptidyl chain, were able to 
inhibit aspartyl-tRNA synthetase. However, this effect was short-lived due to the 
inactivation by acetylation. 
 
Figure 55. structures of derivatives 112a-d and derivatives 113a-e. 
Gadack et al. reported a further attempt to improve the stability of aminoacyl 
sulfamoyl adenosine by synthetizing derivatives lacking of the 5’ oxygen 114a-f  
(Figure 56).241 The rationale was that the lack of the oxygen would improve the 
stability of the resulting aminoacyl sulfamate analogues while making the C-5’ less 
electrophilic and prone attackby N3 adenine, thus avoiding the formation of a cyclic 
degradation product. Unfortunately, no inhibitory activity was observed for these 
derivatives either in vitro or in whole cell assays, except for derivative 114f. This loss 
of activity has been explained by a concomitant loss of affinity for the target due to 
the oxygen deletion. Computer simulations showed that the active compound 114f 
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was the only one capable of binding the aspartyl tRNA synthetase similarly to the 
natural substrate. 
 
Figure 56. Synthesis of 5’-aminoacyl-5’-deoxy-nucleoside sulfonamides 114a-f. 
S-adenosylhomocysteine nucleotidase inhibitors 
5’-methylthioadenosine/S-adenosylhomocysteine (MTA/SAH) nucleosidase is a 
bacterial dual-substrate specific enzyme that catalyses the breakdown of S-
adenosylhomocysteine (SAH) to S-rybosylhomocysteine (SRH) and adenosine (A). It 
is also responsible for the conversion of methylthioadenosine (MTA) in adenine and 
5-thioribose (Figure 57).242 MTA/SAH nucleosidase plays an important role in 
biological polyamine biosynthesis and transmethylation reactions. The inhibition of 
this enzyme causes a feedback inhibition of transmethylation, resulting in the 
formation of uncapped mRNA, which is less efficiently translated. MTA nucleosidase 
is not found in humans and has been shown to be essential in certain bacteria.243 
In the mammalian salvage pathway, MTA phosphorylase is the enzyme responsible 
for the breakdown of MTA to adenine and 5-thioribose 1-phosphate. A careful 
comparison between the E. coli MTA/SAH nucleosidase and the mammalian 
phosphorylase revealed sequence and structure diversity in the active site region. This 
suggested the possibility to achieve substrate specificity244, 245 and these differences 
have been exploited in the design of inhibitors specific for bacterial nucleosidase.  
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Figure 57. MTA/SAH nucleosidases mechanism of action. SAH = S-adenosylhomocysteine; 
SRH = S-ribosylhomocysteine; A = adenine; MTA = 5’ methylthioadenosine = MTR 
=5’-methylthioribose. 
 
Neplanocin A (115) and Aristeromycin (116) are two naturally occurring carbocyclic 
nucleosides exhibiting activity against SAH nucleosidase (Figure 58). 
115 is a carbocyclic analogue of adenosine in which the ribose moiety has been 
replaced by a cyclopentene ring (Figure 58). This analogue was originally isolated 
from Ampuriella regularis and has been reported to have growth inhibitory activity 
against certain fungi.246 Since this analogue was shown to be a strong inhibitor of 
purified calf-liver SAH,247 it was speculated that a possible mode of action for its 
antifungal activity could be the inhibition of bacterial SAH hydrolase. 116 (Figure 58) 
is a carbocyclic analogue of adenosine in which the ribose moiety has been replaced 
by a cyclopentane ring (Figure 58). 116 displays strong activity against some 
phytopathogenic bacteria and fungi, such as X. oryzae and P. oryzae. However, no 
inhibitory activity was reported against yeast and other pathogenic fungi and 
bacteria.248Unfortunately, the close resemblance of 115 and 116 to adenosine renders 
them susceptible to recognition and phosphorylation by cellular kinases, resulting in 
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significant cytotoxicity. Strategic removal of the 4’-hydroxymethyl group of 115 and 
116 to afford the 4’,5’-saturated and 4’,5’-unsaturated derivatives has proven to 
successfully address this limitation, as both families were potent inhibitors of 
SAHase.249, 250 Interestingly, neither series of compounds were substrates for 
adenosine kinase nor adenosine deaminase, thus did not exhibit the toxicity associated 
with 115 and 116. Among these derivatives, 117 was found to inhibit SAH with a Ki 
value of 5 M. However, no antibacterial activity was reported for any of the 
compounds. 
A number of different SAH analogues with structural similarity with the naturally 
occurring nucleoside, S-adenosylhomocysteine were reported by Srivstava et al.251 
These derivatives, when evaluated for their antibacterial and antifungal activities, 
exhibited good to moderate activity against Gram-positive bacteria (group D 
Streptococcus) and some human pathogenic fungi like A. fumigatus, P. marneffei, C. 
albicans, C. neoformans and Mucor sp with MICs ranging from 0.19 to 0.75 M for 
the most active compounds 118a-d (Figure 58).  
5’-Methylthioadenosine analogues have been described as inhibitors of MTA/SAH 
nucleosidase. Among them, 119a (MTDIA), and 119b have been reported to be 
femtomolar inhibitors of E. coli MTA nucleotidase (Figure 58).252, 253 Unfortunately, 
no activities in whole cell assay have been reported so far. 
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Figure 58. Structures of natural antibiotic Neplanocin A (115) and Aristeromycin (116) and synthetic 
MTA/SAH nucleotidase inhibitors 117; 118a-d; 119a,b. 
 
Bacterial cell division 
 
FtsZ is an essential bacterial cytoskeletal protein, and represents the prokaryotic 
counterpart of tubulin. 254 In vivo polymerization of FtsZ is a GTP-induced process 
that leads to the formation of a macromolecular structure termed the Z ring.255 This is 
a key event in bacterial cell division. Agents interfering with FtsZ polymerization 
potently inhibit septum formation and cell division, and may be developed into a 
promising class of novel antibiotics with low potential for cross resistance.256 FtsZ 
shows only weak sequence identity to the eukaryotic tubulin, although it has a similar 
three-dimensional structure and conserved longitudinal protofilament contacts.224 
Modified GTP analogues 120a-k bearing small substituents in C-8 position on the 
guanine ring were found to inhibit FtsZ (Figure 59).257 
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Figure 59. Structures of FtsZ inhibitors (120a-k). 
 
They exert their action by binding the enzyme, with the C-8 substituents capable of 
obstructing the association of a second FtsZ subunit. Compounds with small C-8 
substituent did not inhibit tubulin polymerisation, a prerequisite for suitable selective 
and non-cytotoxic agents. Although these analogues do not have a druglike structure, 
they may represent a starting point for the further development of more bioavailable 
FtsZ inhibitors. 
Teichoic acid biosynthesis 
Lipoteichoic acids (LTAs) and wall teichoic acids (WTAs) are cell wall polymers that 
play fundamental roles in Gram-positive bacterial physiology and pathogenesis, and 
have both been proposed as novel antibacterial targets.258 LTAs and WTAs play 
critical roles in bacterial viability in vitro.259 LTA (D)-alanylation is a step in teichoic 
acid biosynthesis that crucially has no counterpart in the human body and can be 
inhibited by (5’-O-[N-(D-alanyl)-sylfamoyl]adenosine (121) (Figure 60) (Ki = 232 
nM).260  
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Figure 60. Structure of 5’-O-[N-(D-alanyl)-sulfamoyl]adenosine (121). 
 
Whole cell studies were carried out inhibiting LTA (D)-alanylation in wild type B. 
subtilis using this analogue in combination with vancomycin at a concentration of 
respectively 1 mM and 0.4 nM. No growth was observed after 30 h treatment. In the 
presence of vancomycin alone, the wild type recovers its growth after 12 h incubation 
and, after 30 h, reached an attenuance comparable to that of untreated wild type 
cells.260 
Conclusion and future direction 
The development of antimicrobial resistance is a natural phenomenon and represents a 
serious and growing problem in the treatment of bacterial infections. The slowdown 
in development of new antibacterial drugs has coincided with an alarming increase in 
the number of resistant, multi-resistant, and even totally resistant bacterial infections. 
At the same time, there has also been an increase in the incidence of fungal infections, 
which has been also linked to the emergence of antifungal drug resistance. The rise in 
the occurrence of drug resistant infections has intensified the need for the 
development of a new generation of antibacterial and antifungal agents. The 
inappropriate use of antimicrobial drugs, including in animal husbandry, favoured the 
emergence and selection of resistant strains. This, in combination with poor infection 
prevention and control practices, contributes to further emergence and spread of 
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antimicrobial resistance. It is alarming that in countries where antibiotics can be 
bought without a prescription, emergence and spread of resistance is worse in 
comparison with countries were this practice is under strict control. Therefore, in our 
vision, the most urgent point to focus on is the education of the world population. 
Surveillance data from hospitals and farm veterinary must be extensively used for this 
purpose with the intent to achieve a better control of antibiotic dosage and use. This is 
because the pace at which the research for novel antibiotic proceeds is inadequate to 
cope with the spread of bacterial resistance. At the same time, scientists from 
academia and industry, must work together to develop new antibiotics.  
Alongside the human health concerns it is important to note that when infections 
become resistant to first-line drugs, more expensive therapies must be used. A longer 
duration of illness and treatment increases health care costs as well as the economic 
burden on families and societies. 
We have shown here that nucleoside analogues have a great potential as antibiotic 
agents, and are capable of targeting essential cellular processes. Antibiotic nucleoside 
analogue targets include: cell wall growth (MrY and CS inhibitors); nucleic acid 
synthesis; translation (aatRNA synthase and ribosomal peptidyl center inhibitors) and 
nucleotide metabolism of bacterial and fungal pathogens (phosphoribosyltransferase, 
guanosine monophosphate synthase, inosine-5-monophosphate dehydrogenase 
inhibitors).  We have also discussed how nucleoside analogues can affect new or 
poorly characterized targets. Such targets include enzymes involved in a range of 
processes such as: cell wall biosynthesis (Mur A); in the later lipid-linked steps 
encompassing both LTA and WTA synthesis (dtA); in microbial cell division (FtsZ) 
and methionine salvage pathway (SAH/MTA nucleosidase). Other processes such as 
cell signalling in bacteria mediated by the rei protein,261, 262 and protein 
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glycosylation263 have also been recently identified as potential new targets for 
nucleoside-based antibiotic agents. These processes, constitute a rich source of crucial 
targets for antibacterial chemotherapy. Since most of these pathways are unique to 
bacteria further investigations of the mechanisms involved could help to identify new 
drug targets.  Several groups are already exploiting some of these targets e.g. 
NovoBiotic Pharmaceuticals, which discovered teixobactin, a new Gram-positive 
bacteria-targeting antibiotic.7 This new cell wall inhibitor (lipid III) is able to kill 
pathogens such as MRSA and M. tuberculosis without detectable resistance. 
Scientists at Merck have also recently identified specific inhibitors of either early or 
late stage of WTA synthesis.264 Some of these new compounds do not have intrinsic 
bioactivity but rather demonstrate potent bactericidal synergy in combination with 
broad-spectrum -lactam antibiotics against diverse clinical isolates of MRSA. The 
combination has also demonstrated robust efficacy in a murine infection model of 
MRSA, proving that drug combination can be a valuable approach to tackle antibiotic 
resistance. It is important to mention that another recently developed approach 
involved generating compounds that inhibit bacterial virulence and biofilm formation, 
by controlling the quorum sensing.265 This alternative approach does not involve the 
killing of the pathogen and therefore does not put on it a pressure to develop 
resistance. 
We believe that structure-function-based studies on novel and underutilized targets, 
essential to bacterial and fungal viability, could help the optimization of the already 
known nucleoside antibiotics portfolio and aid the identification of new antibacterial 
and antifungal agents. The discovery of new nucleoside-based molecules could 
originate from the exploitation of techniques such as genome mining,266 analysis of 
DNA sequence and semi-synthesis,267 along with the investigation of metabolites 
  87 
from microorganisms from unusual habitats, such as marine microorganisms and 
uncultured terrestrial microorganisms.268, 269 Moreover, mutasynthesis270 and 
combinatorial biosynthesis271 can be employed to generate new variants or hybrid 
nucleoside antibiotics.  
Alongside these strategies is the chemical modification of existing structures via 
classic organic synthesis. Although more time consuming, and generally more 
challenging, this strategy can be more flexible in terms of novelty of the structural 
diversification. From the above discussion, it is clear that the majority of the 
nucleoside antibiotics, both natural and man-made, have the problem of being poorly 
available to their biological target because their intrinsic low permeability through the 
cellular membrane. It is our opinion that synthetic efforts should be directed toward 
the identification of suitable structural motif capable of increasing the cell-
permeability of the new structures without compromising the biological activity. To 
overcome the poor permeation of aminoacyl-adenylates into bacterial cells, the active 
component can be conjugated with a specialized module that facilitates its active 
transport into bacterial cell. In this regard, prodrug approaches, currently successfully 
used in antiviral and anticancer nucleosides, can be a key answer to the poor 
permeability problem. For example, our research group hasshown that the 
pronucleotide (proTide) methodology could be used for the development of active 
molcules against M. tuberculosis and reveals the importance of improving 
lipophilicity to efficiently pass the mycobacteria wall barrier.272 Prodrug approaches 
in combination with a detailed understanding of the biosynthetic pathways of 
nucleoside-based natural products can be effectively implemented with the use of 
advanced molecular modelling tools and computer aided drug design.  
As far as fungi are concerned, nucleoside analogues capable of interfering with the 
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cell wall synthesis suffer from the same problem as their counterpart in bacteria: 
penetration of the fungal cell. The majority of chitin synthase inhibitors are peptide-
nucleoside structure that relies on peptide transporter to access the cell. Modification 
of the peptide part with more lipophilic amino acids (natural and non-natural) could 
be an effective strategy to improve their in vivo antifungal activity. More lipophilic, 
fluorinated amino acids for example could be structural motifs that may have some 
success in this respect. It is our opinion that the chemists have at their disposal several 
potentially effective approaches that have never been used in the 
antibacterial/antifungal research. For example, the large amount of sugar units in 
bacterial and fungal cells can be used as target for boron functionalized 
compounds.273 Molecules functionalized with boron can have great affinity for the 
sugar’s hydroxyl group. This can be exploited by establishing selective interactions 
with the critical enzymes (such as chitin synthase): thereby stopping the formation of 
chitin or glycoproteins important for the cell wall. Research in this field should be 
pursued with great efforts especially in light of the great progress that boron 
chemistry has made in recent years. In terms of future drug discovery strategies, it is 
our view that it will be important to continue to pursue approaches that are likely to 
minimise, or delay, resistance to a specific molecule by targeting diverse biologically 
relevant pathways in the bacterial/fungal cell simultaneously. 
In conclusion, we strongly believe that nucleoside and nucleotide analogues will play 
a key role in the quest for more effective antibiotics. Furthermore, there are several 
bacterial and fungal targets such as bacterial cell division protein (FtsZ) and teichoic 
acids biosynthesis for which very few nucleosides have been explored as potential 
therapeutics. We predict that expansion of this promising field of research would lead 
to the implementation of an effective new arsenal against bacterial and fungal 
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resistance. 
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